STEPAN CO - Quarter Report: 2021 March (Form 10-Q)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(MARK ONE)
☒ |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2021
☐ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
FOR THE TRANSITION PERIOD FROM TO
Commission File Number 1-4462
STEPAN COMPANY
(Exact name of registrant as specified in its charter)
Delaware |
|
36-1823834 |
(State or other jurisdiction |
|
(I.R.S. Employer |
of incorporation or organization) |
|
Identification Number) |
22 West Frontage Road, Northfield, Illinois 60093
(Address of principal executive offices)
Registrant’s telephone number (847) 446-7500
Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of each class |
|
Trading symbol(s) |
|
Name of each exchange on which registered |
Common Stock, $1 par value |
|
SCL |
|
New York Stock Exchange |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer |
|
☒ |
|
Accelerated filer |
|
☐ |
|
|
|
|
|||
Non-accelerated filer |
|
☐ |
|
Smaller reporting company |
|
☐ |
|
|
|
|
|
|
|
Emerging growth company |
|
☐ |
|
|
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes ☐ No ☒
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
Class |
|
Outstanding at April 23, 2021 |
Common Stock, $1 par value |
|
22,516,933 Shares |
Part I FINANCIAL INFORMATION
Item 1 - Financial Statements
STEPAN COMPANY
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
Unaudited
(In thousands, except per share amounts) |
|
Three Months Ended March 31 |
|
|||||
|
|
2021 |
|
|
2020 |
|
||
Net Sales |
|
$ |
537,740 |
|
|
$ |
449,987 |
|
Cost of Sales |
|
|
428,760 |
|
|
|
370,718 |
|
Gross Profit |
|
|
108,980 |
|
|
|
79,269 |
|
Operating Expenses: |
|
|
|
|
|
|
|
|
Selling |
|
|
14,504 |
|
|
|
13,532 |
|
Administrative |
|
|
22,638 |
|
|
|
18,872 |
|
Research, development and technical services |
|
|
15,149 |
|
|
|
13,827 |
|
Deferred compensation (income) expense |
|
|
2,694 |
|
|
|
(7,323 |
) |
|
|
|
54,985 |
|
|
|
38,908 |
|
Business restructuring expenses (Note 16) |
|
|
(81 |
) |
|
|
(357 |
) |
Operating Income |
|
|
53,914 |
|
|
|
40,004 |
|
Other Income (Expense): |
|
|
|
|
|
|
|
|
Interest, net |
|
|
(1,524 |
) |
|
|
(1,230 |
) |
Other, net (Note 15) |
|
|
746 |
|
|
|
(3,262 |
) |
|
|
|
(778 |
) |
|
|
(4,492 |
) |
|
|
|
|
|
|
|
|
|
Income Before Provision for Income Taxes |
|
|
53,136 |
|
|
|
35,512 |
|
Provision for Income Taxes |
|
|
12,525 |
|
|
|
7,973 |
|
Net Income |
|
|
40,611 |
|
|
|
27,539 |
|
Net Loss Attributable to Noncontrolling Interests (Note 2) |
|
|
— |
|
|
|
6 |
|
Net Income Attributable to Stepan Company |
|
$ |
40,611 |
|
|
$ |
27,545 |
|
|
|
|
|
|
|
|
|
|
Net Income Per Common Share Attributable to Stepan Company (Note 10): |
|
|
|
|
|
|
|
|
Basic |
|
$ |
1.77 |
|
|
$ |
1.20 |
|
Diluted |
|
$ |
1.74 |
|
|
$ |
1.18 |
|
|
|
|
|
|
|
|
|
|
Shares Used to Compute Net Income Per Common Share Attributable to Stepan Company (Note 10): |
|
|
|
|
|
|
|
|
Basic |
|
|
22,974 |
|
|
|
23,023 |
|
Diluted |
|
|
23,330 |
|
|
|
23,285 |
|
|
|
The accompanying Notes to Condensed Consolidated Financial Statements are an integral part of these financial statements.
2
STEPAN COMPANY
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
Unaudited
(In thousands) |
|
Three Months Ended March 31 |
|
|||||
|
|
2021 |
|
|
2020 |
|
||
Net Income |
|
$ |
40,611 |
|
|
$ |
27,539 |
|
Other Comprehensive Income: |
|
|
|
|
|
|
|
|
Foreign currency translation adjustments (1) (Note 11) |
|
|
(18,441 |
) |
|
|
(41,195 |
) |
Defined benefit pension adjustments, net of tax (Note 11) |
|
|
874 |
|
|
|
808 |
|
Derivative instrument activity, net of tax (Note 11) |
|
|
(2 |
) |
|
|
(2 |
) |
Total Other Comprehensive Income |
|
|
(17,569 |
) |
|
|
(40,389 |
) |
Comprehensive Income |
|
|
23,042 |
|
|
|
(12,850 |
) |
Comprehensive Income Attributable to Noncontrolling Interest (Note 2) |
|
|
8 |
|
|
|
19 |
|
Comprehensive Income Attributable to Stepan Company |
|
$ |
23,050 |
|
|
$ |
(12,831 |
) |
(1) |
Includes foreign currency translation adjustments related to noncontrolling interest. |
|
The accompanying Notes to Condensed Consolidated Financial Statements are an integral part of these financial statements.
3
STEPAN COMPANY
CONDENSED CONSOLIDATED BALANCE SHEETS
Unaudited
(Dollars in thousands) |
|
March 31, 2021 |
|
|
December 31, 2020 |
|
|||
Assets |
|
|
|
|
|
|
|
|
|
Current Assets: |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
150,692 |
|
|
$ |
349,938 |
|
|
Receivables, net |
|
|
380,649 |
|
|
|
301,318 |
|
|
Inventories (Note 6) |
|
|
235,062 |
|
|
|
218,783 |
|
|
Other current assets |
|
|
31,250 |
|
|
|
35,612 |
|
|
Total current assets |
|
|
797,653 |
|
|
|
905,651 |
|
|
Property, Plant and Equipment: |
|
|
|
|
|
|
|
|
|
Cost |
|
|
1,949,681 |
|
|
|
1,872,650 |
|
|
Less: Accumulated depreciation |
|
|
(1,203,302 |
) |
|
|
(1,189,983 |
) |
|
Property, plant and equipment, net |
|
|
746,379 |
|
|
|
682,667 |
|
|
Goodwill, net (Note 17) |
|
|
96,252 |
|
|
|
27,972 |
|
|
Other intangible assets, net (Note 17) |
|
|
66,813 |
|
|
|
24,068 |
|
|
Long-term investments (Note 3) |
|
|
30,212 |
|
|
|
30,652 |
|
|
Operating lease assets |
|
|
72,157 |
|
|
|
62,421 |
|
|
Other non-current assets |
|
|
18,473 |
|
|
|
18,905 |
|
|
Total assets |
|
$ |
1,827,939 |
|
|
$ |
1,752,336 |
|
|
Liabilities and Equity |
|
|
|
|
|
|
|
|
|
Current Liabilities: |
|
|
|
|
|
|
|
|
|
Current maturities of long-term debt (Note 14) |
|
$ |
87,525 |
|
|
$ |
37,857 |
|
|
Accounts payable |
|
|
264,192 |
|
|
|
236,750 |
|
|
Accrued liabilities |
|
|
112,372 |
|
|
|
141,947 |
|
|
Total current liabilities |
|
|
464,089 |
|
|
|
416,554 |
|
|
Deferred income taxes |
|
|
29,876 |
|
|
|
20,745 |
|
|
Long-term debt, less current maturities (Note 14) |
|
|
160,847 |
|
|
|
160,812 |
|
|
Non-current operating lease liabilities |
|
|
60,433 |
|
|
|
51,567 |
|
|
Other non-current liabilities |
|
|
108,748 |
|
|
|
114,293 |
|
|
Commitments and Contingencies (Note 8) |
|
|
|
|
|
|
|
|
|
Equity: |
|
|
|
|
|
|
|
|
|
Common stock, $1 par value; authorized 60,000,000 shares; Issued 26,725,620 shares in 2021 and 26,658,032 shares in 2020 |
|
|
26,726 |
|
|
|
26,658 |
|
|
Additional paid-in capital |
|
|
209,471 |
|
|
|
206,716 |
|
|
Accumulated other comprehensive loss (Note 11) |
|
|
(154,442 |
) |
|
|
(136,881 |
) |
|
Retained earnings |
|
|
1,057,579 |
|
|
|
1,023,829 |
|
|
Less: Common treasury stock, at cost, 4,208,867 shares in 2021 and 4,185,242 shares in 2020 |
|
|
(137,052 |
) |
|
|
(133,629 |
) |
|
Total Stepan Company stockholders’ equity |
|
|
1,002,282 |
|
|
|
986,693 |
|
|
Noncontrolling interests (Note 2) |
|
|
1,664 |
|
|
|
1,672 |
|
|
Total equity |
|
|
1,003,946 |
|
|
|
988,365 |
|
|
Total liabilities and equity |
|
$ |
1,827,939 |
|
|
$ |
1,752,336 |
|
The accompanying Notes to Condensed Consolidated Financial Statements are an integral part of these financial statements.
4
STEPAN COMPANY
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Unaudited
(In thousands) |
|
Three Months Ended March 31 |
|
|||||
|
|
2021 |
|
|
2020 |
|
||
Cash Flows From Operating Activities |
|
|
|
|
|
|
|
|
Net income |
|
$ |
40,611 |
|
|
$ |
27,539 |
|
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
22,060 |
|
|
|
20,023 |
|
Deferred compensation |
|
|
2,694 |
|
|
|
(7,323 |
) |
Realized and unrealized (gains) losses on long-term investments |
|
|
(534 |
) |
|
|
3,875 |
|
Stock-based compensation |
|
|
2,539 |
|
|
|
1,202 |
|
Deferred income taxes |
|
|
2,481 |
|
|
|
131 |
|
Other non-cash items |
|
|
(40 |
) |
|
|
395 |
|
Changes in assets and liabilities: |
|
|
|
|
|
|
|
|
Receivables, net |
|
|
(63,243 |
) |
|
|
(30,767 |
) |
Inventories |
|
|
(7,476 |
) |
|
|
(447 |
) |
Other current assets |
|
|
(861 |
) |
|
|
(3,180 |
) |
Accounts payable and accrued liabilities |
|
|
(9,377 |
) |
|
|
(16,583 |
) |
Pension liabilities |
|
|
(451 |
) |
|
|
(236 |
) |
Environmental and legal liabilities |
|
|
(21 |
) |
|
|
(947 |
) |
Deferred revenues |
|
|
(80 |
) |
|
|
(157 |
) |
Net Cash Used In Operating Activities |
|
|
(11,698 |
) |
|
|
(6,475 |
) |
Cash Flows From Investing Activities |
|
|
|
|
|
|
|
|
Expenditures for property, plant and equipment |
|
|
(37,632 |
) |
|
|
(33,202 |
) |
Asset acquisition (Note 17) |
|
|
(3,503 |
) |
|
|
(2,040 |
) |
Business acquisition, net of cash acquired (Note 17) |
|
|
(184,000 |
) |
|
|
— |
|
Other, net |
|
|
1,379 |
|
|
|
2,331 |
|
Net Cash Used In Investing Activities |
|
|
(223,756 |
) |
|
|
(32,911 |
) |
Cash Flows From Financing Activities |
|
|
|
|
|
|
|
|
Revolving debt and bank overdrafts, net |
|
|
49,668 |
|
|
|
— |
|
Dividends paid |
|
|
(6,861 |
) |
|
|
(6,202 |
) |
Company stock repurchased |
|
|
(989 |
) |
|
|
(7,243 |
) |
Stock option exercises |
|
|
381 |
|
|
|
155 |
|
Other, net |
|
|
(2,272 |
) |
|
|
(1,128 |
) |
Net Cash (Used In) Provided By Financing Activities |
|
|
39,927 |
|
|
|
(14,418 |
) |
Effect of Exchange Rate Changes on Cash |
|
|
(3,719 |
) |
|
|
(7,240 |
) |
Net Decrease in Cash and Cash Equivalents |
|
|
(199,246 |
) |
|
|
(61,044 |
) |
Cash and Cash Equivalents at Beginning of Period |
|
|
349,938 |
|
|
|
315,383 |
|
Cash and Cash Equivalents at End of Period |
|
$ |
150,692 |
|
|
$ |
254,339 |
|
Supplemental Cash Flow Information |
|
|
|
|
|
|
|
|
Cash payments of income taxes, net of refunds/payments |
|
$ |
6,638 |
|
|
$ |
3,316 |
|
Cash payments of interest |
|
$ |
2,242 |
|
|
$ |
2,122 |
|
The accompanying Notes to Condensed Consolidated Financial Statements are an integral part of these financial statements.
5
STEPAN COMPANY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
March 31, 2021
Unaudited
1. |
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS |
The condensed consolidated financial statements included herein have been prepared by Stepan Company (the Company), without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) have been condensed or omitted pursuant to such rules and regulations, although management believes that the disclosures are adequate and make the information presented not misleading. In the opinion of management, all adjustments, consisting only of normal recurring accruals, necessary to present fairly the Company’s financial position as of March 31, 2021, and its results of operations and cash flows for the three months ended March 31, 2021 and 2020, have been included. These financial statements and related footnotes should be read in conjunction with the financial statements and related footnotes included in the Company’s 2020 Annual Report on Form 10-K.
2. |
RECONCILIATIONS OF EQUITY |
Below are reconciliations of total equity, Company equity and equity attributable to noncontrolling interests for the three months ended March 31, 2021 and 2020:
(In thousands, except share and per share amounts) |
|
Total |
|
|
Common Stock |
|
|
Additional Paid-in Capital |
|
|
Common Treasury Stock |
|
|
Accumulated Other Comprehensive Income (Loss) |
|
|
Retained Earnings |
|
|
Noncontrolling Interest (1) |
|
|||||||
Balance, December 31, 2020 |
|
$ |
988,365 |
|
|
$ |
26,658 |
|
|
$ |
206,716 |
|
|
$ |
(133,629 |
) |
|
$ |
(136,881 |
) |
|
$ |
1,023,829 |
|
|
$ |
1,672 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of 5,786 shares of common stock under stock option plan |
|
|
381 |
|
|
|
6 |
|
|
|
375 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchase of 8,300 shares of common stock |
|
|
(989 |
) |
|
|
— |
|
|
|
— |
|
|
|
(989 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock-based and deferred compensation |
|
|
8 |
|
|
|
62 |
|
|
|
2,380 |
|
|
|
(2,434 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income |
|
|
40,611 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
40,611 |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other comprehensive income (loss) |
|
|
(17,569 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(17,561 |
) |
|
|
— |
|
|
|
(8 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash dividends paid: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock ($0.305 per share) |
|
|
(6,861 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(6,861 |
) |
|
|
— |
|
Balance, March 31, 2021 |
|
$ |
1,003,946 |
|
|
$ |
26,726 |
|
|
$ |
209,471 |
|
|
$ |
(137,052 |
) |
|
$ |
(154,442 |
) |
|
$ |
1,057,579 |
|
|
$ |
1,664 |
|
6
(In thousands, except share and per share amounts) |
|
Total |
|
|
Common Stock |
|
|
Additional Paid-in Capital |
|
|
Common Treasury Stock |
|
|
Accumulated Other Comprehensive Income (Loss) |
|
|
Retained Earnings |
|
|
Noncontrolling Interest (1) |
|
|||||||
Balance, December 31, 2019 |
|
$ |
892,496 |
|
|
$ |
26,493 |
|
|
$ |
193,135 |
|
|
$ |
(114,139 |
) |
|
$ |
(136,170 |
) |
|
$ |
922,464 |
|
|
$ |
713 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of 2,747 shares of common stock under stock option plan |
|
|
155 |
|
|
|
3 |
|
|
|
152 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchase of 89,225 shares of common stock |
|
|
(7,243 |
) |
|
|
— |
|
|
|
— |
|
|
|
(7,243 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock-based and deferred compensation |
|
|
1,116 |
|
|
|
45 |
|
|
|
2,374 |
|
|
|
(1,303 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income |
|
|
27,539 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
27,545 |
|
|
|
(6 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other comprehensive income (loss) |
|
|
(40,389 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(40,376 |
) |
|
|
— |
|
|
|
(13 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash dividends paid: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock ($0.275 per share) |
|
|
(6,202 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(6,202 |
) |
|
|
— |
|
Balance, March 31, 2020 |
|
$ |
867,472 |
|
|
$ |
26,541 |
|
|
$ |
195,661 |
|
|
$ |
(122,685 |
) |
|
$ |
(176,546 |
) |
|
$ |
943,807 |
|
|
$ |
694 |
|
|
(1) |
Reflects the noncontrolling interest in the Company’s China joint venture. |
|
3. |
FAIR VALUE MEASUREMENTS |
The following were the financial instruments held by the Company at March 31, 2021, and December 31, 2020, and the methods and assumptions used to estimate the instruments’ fair values:
Cash and cash equivalents
Carrying value approximated fair value because of the short maturity of the instruments. Fair value of cash and cash equivalents is a Level 1 measurement.
Derivative assets and liabilities
Derivative assets and liabilities include the foreign currency exchange contracts discussed in Note 4, Derivate Instruments, of the notes to the Company’s condensed consolidated financial statements (included in Item 1 of this Form 10-Q). Fair value and carrying value were the same because the contracts were recorded at fair value. The fair values of the foreign currency contracts were calculated as the difference between the applicable forward foreign exchange rates at the reporting date and the contracted foreign exchange rates multiplied by the contracted notional amounts. See the table below that describes financial assets and liabilities measured on a recurring basis for the reported fair values of derivative assets and liabilities.
Long-term investments
Long-term investments include the mutual fund assets the Company held to fund a portion of its deferred compensation liabilities and all of its non-qualified supplemental executive defined contribution obligations (see the defined contribution plans section of Note 9, Postretirement Benefit Plans, of the notes to the Company’s condensed consolidated financial statements (included in Item 1 of this Form 10-Q)). Fair value and carrying value were the same because the mutual fund assets were recorded at fair value. Fair values for the mutual funds were calculated using the published market price per unit at the reporting date multiplied by the number of units held at the reporting date. See the table that follows the financial instrument descriptions for the reported fair value of long-term investments.
Debt obligations
The fair value of debt with original maturities greater than one year comprised the combined present values of scheduled principal and interest payments for each of the various loans, individually discounted at rates equivalent to those which could be obtained by the Company for new debt issues with durations equal to the average life to maturity of each loan. The fair values of the remaining Company debt obligations approximated their carrying values due to the short-term nature of the debt. The Company’s fair value measurements for debt fall within level 2 of the fair value hierarchy.
7
At March 31, 2021, and December 31, 2020, the fair values and related carrying values of debt, including current maturities, were as follows (the fair value and carrying value amounts are presented without regard to unamortized debt issuance costs of $582,000 and $617,000 as of March 31, 2021 and December 31, 2020, respectively):
(In thousands) |
|
March 31, 2021 |
|
|
December 31, 2020 |
|
||
Fair value |
|
$ |
259,889 |
|
|
$ |
210,370 |
|
Carrying value |
|
|
248,954 |
|
|
|
199,286 |
|
The following tables present financial assets and liabilities, excluding cash and cash equivalents, measured on a recurring basis at fair value as of March 31, 2021, and December 31, 2020, and the level within the fair value hierarchy in which the fair value measurements fall:
(In thousands) |
|
March 2021 |
|
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
||||
Mutual fund assets |
|
$ |
30,212 |
|
|
$ |
30,212 |
|
|
$ |
— |
|
|
$ |
— |
|
Derivative assets: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign currency contracts |
|
|
231 |
|
|
|
— |
|
|
|
231 |
|
|
|
— |
|
Total assets at fair value |
|
$ |
30,443 |
|
|
$ |
30,212 |
|
|
$ |
231 |
|
|
$ |
— |
|
Derivative liabilities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign currency contracts |
|
$ |
196 |
|
|
$ |
— |
|
|
$ |
196 |
|
|
$ |
— |
|
(In thousands) |
|
December 2020 |
|
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
||||
Mutual fund assets |
|
$ |
30,652 |
|
|
$ |
30,652 |
|
|
$ |
— |
|
|
$ |
— |
|
Derivative assets: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign currency contracts |
|
|
335 |
|
|
|
— |
|
|
|
335 |
|
|
|
— |
|
Total assets at fair value |
|
$ |
30,987 |
|
|
$ |
30,652 |
|
|
$ |
335 |
|
|
$ |
— |
|
Derivative liabilities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign currency contracts |
|
$ |
566 |
|
|
$ |
- |
|
|
$ |
566 |
|
|
$ |
— |
|
4. |
DERIVATIVE INSTRUMENTS |
The Company is exposed to certain risks relating to its ongoing business operations. The primary risk managed by the use of derivative instruments is foreign currency exchange risk. The Company holds forward foreign currency exchange contracts that are not designated as any type of accounting hedge as defined by GAAP. The Company uses these contracts to manage its exposure to exchange rate fluctuations on certain Company subsidiary cash, accounts receivable, accounts payable and other obligation balances that are denominated in currencies other than the entities’ functional currencies. The forward foreign exchange contracts are recognized on the balance sheet as either an asset or a liability measured at fair value. Gains and losses arising from recording the foreign exchange contracts at fair value are reported in earnings as offsets to the losses and gains reported in earnings arising from the re-measurement of the asset and liability balances into the applicable functional currencies. At March 31, 2021, and December 31, 2020, the Company had open forward foreign currency exchange contracts, all with durations of one to three months, to buy or sell foreign currencies with U.S. dollar equivalent amounts of $46,640,000 and $48,336,000, respectively.
The fair values of the derivative instruments held by the Company on March 31, 2021, and December 31, 2020, are disclosed in Note 3, Fair Value Measurements, of the notes to the Company’s condensed consolidated financial statements (included in Item 1 of this Form 10-Q). Derivative instrument gains and losses for the three-month periods ended March 31, 2021 and 2020, were immaterial. For amounts reclassified out of accumulated other comprehensive income (loss) (AOCI) into earnings for the three-month periods ended March 31, 2021 and 2020, see Note 11, Accumulated Other Comprehensive Income (Loss), of the notes to the Company’s condensed consolidated financial statements (included in Item 1 of this Form 10-Q).
5. |
STOCK-BASED COMPENSATION |
On March 31, 2021, the Company had stock options, stock awards and stock appreciation rights (SARs) outstanding under its 2011 Incentive Compensation Plan. SARs granted prior to 2015 are cash-settled, and SARs granted in 2015 and later are stock-settled. Stock options and SARs granted prior to 2017 generally cliff vested after two years. Starting in 2017, stock options and
8
SARs have a graded vesting feature, with of the awards vesting each year. The Company has elected the straight-line method of expense attribution for the stock options and SARs with the graded vesting feature.
Compensation expense recorded for all stock options, stock awards and SARs was as follows:
(In thousands) |
|
|||||
Three Months Ended March 31 |
|
|||||
2021 |
|
|
2020 |
|
||
$ |
2,540 |
|
|
$ |
1,202 |
|
The increase in stock-based compensation expense for the first quarter of 2021 compared to the first quarter of 2020 was primarily attributable to cash-settled SARs. The increase in cash-settled SARs compensation expense reflects an increase in the market value of Company stock during the first quarter of 2021 versus a decrease in the market value of Company stock during the first quarter of 2020.
Unrecognized compensation costs for stock options, stock awards and SARs were as follows:
(In thousands) |
|
March 31, 2021 |
|
|
December 31, 2020 |
|
||
Stock options |
|
$ |
3,780 |
|
|
$ |
1,993 |
|
Stock awards |
|
|
8,674 |
|
|
|
5,313 |
|
SARs |
|
|
8,176 |
|
|
|
4,341 |
|
The increases in unrecognized compensation costs for stock options, stock awards and SARs reflected the 2021 grants of:
|
|
Shares |
|
|
Stock options |
|
|
66,134 |
|
Stock awards (at target) |
|
|
41,228 |
|
SARs |
|
|
142,451 |
|
The unrecognized compensation costs at March 31, 2021, are expected to be recognized over weighted-average periods of 2.2 years for stock options, 2.1 years for stock awards and 2.2 years for SARs.
6. |
INVENTORIES |
The composition of inventories at March 31, 2021, and December 31, 2020, was as follows:
(In thousands) |
|
March 31, 2021 |
|
|
December 31, 2020 |
|
||
Finished goods |
|
$ |
156,228 |
|
|
$ |
148,878 |
|
Raw materials |
|
|
78,834 |
|
|
|
69,905 |
|
Total inventories |
|
$ |
235,062 |
|
|
$ |
218,783 |
|
7. |
LEASES |
The Company’s operating leases are primarily comprised of railcar, real estate, storage tank, auto, trailer and manufacturing/office equipment leases. Railcars and real estate comprise approximately 24 percent and 62 percent, respectively, of the Company’s consolidated ROU asset balance. Except for real estate, typical lease terms range from one to ten years. Real estate lease terms typically range from one to fifty years. The Company’s four principal real estate leases relate to the office lease for the new corporate headquarters in Northbrook, Illinois and land leases in the Philippines, Singapore and Lake Providence, Louisiana. As of March 31, 2021, the Company had a storage tank lease, valued at approximately $168,000, that had not commenced. This lease will commence in the second quarter of 2021 with a lease term of two years.
As most of the Company’s leases do not provide an implicit borrowing rate, the Company uses its incremental borrowing rate (IBR) based on the information available at the commencement date in determining the present value of lease payments. IBRs were specifically determined for the United States, Philippines, Singapore, Brazil and China, typically for five-year increments. The U.S. IBR was used for all other countries as the leases in these countries are not material. The total value of leases that reside in the five countries identified above represents approximately 98 percent of the Company’s consolidated
9
ROU asset balance. Lease cost is included in the Cost of Sales and Operating Expenses sections of the Condensed Consolidated Statements of Income.
(In thousands) |
|
March 31, 2021 |
|
|
Lease Cost |
|
|
|
|
Operating lease cost |
|
$ |
3,726 |
|
Short-term lease cost |
|
|
1,269 |
|
Variable lease cost |
|
|
283 |
|
Total lease cost |
|
$ |
5,278 |
|
Other Information |
|
|
|
|
Cash paid for amounts included in the measurement of lease liabilities: |
|
|
|
|
Operating cash flow from operating leases |
|
$ |
3,289 |
|
Right-of-use assets obtained in exchange for new operating lease liabilities |
|
|
12,627 |
|
(In thousands) |
|
|
|
|
Undiscounted Cash Flows: |
|
|
|
|
2021 (excluding the three months ended March 31, 2021) |
|
$ |
10,753 |
|
2022 |
|
|
13,081 |
|
2023 |
|
|
10,847 |
|
2024 |
|
|
6,935 |
|
2025 |
|
|
5,306 |
|
Subsequent to 2025 |
|
|
39,647 |
|
Total Undiscounted Cash Flows |
|
$ |
86,569 |
|
Less: Imputed interest |
|
|
(13,765 |
) |
Present value |
|
$ |
72,804 |
|
Current operating lease liabilities (1) |
|
|
12,371 |
|
Non-current operating lease liabilities |
|
|
60,433 |
|
Total lease liabilities |
|
$ |
72,804 |
|
|
(1) |
This item is included in the Accrued liabilities line on the Company’s Condensed Consolidated Balance Sheet. |
Weighted-average remaining lease term-operating leases |
|
10 years |
|
|
Weighted-average discount rate-operating leases |
|
|
3.0 |
% |
8. |
CONTINGENCIES |
There are a variety of legal proceedings pending or threatened against the Company that occur in the normal course of the Company’s business, the majority of which relate to environmental assessment, protection and remediation matters. Some of these proceedings may result in fines, penalties, judgments or costs being assessed against the Company at some future time. The Company’s operations are subject to extensive local, state and federal regulations, including the U.S. Comprehensive Environmental Response, Compensation and Liability Act of 1980 (CERCLA) and the Superfund amendments of 1986 (Superfund) as well as comparable regulations applicable to the Company’s foreign locations. Over the years, the Company has received requests for information related to or has been named by government authorities as a potentially responsible party (PRP) at a number of sites where cleanup costs have been or may be incurred by the Company under CERCLA and similar state statutes. In addition, damages are being claimed against the Company in general liability actions for alleged personal injury or property damage in the case of some disposal and plant sites. The Company believes that it has made adequate provisions for the costs it is likely to incur with respect to these sites and claims.
In determining the appropriate level of environmental reserves, the Company considers several factors such as information obtained from investigatory studies; changes in the scope of remediation; the interpretation, application and enforcement of laws and regulations; changes in the costs of remediation programs; the development of alternative cleanup technologies and methods; and the relative level of the Company’s involvement at various sites for which the Company is allegedly associated. The level of annual expenditures for remedial, monitoring and investigatory activities will change in the future as major components of planned remediation activities are completed and the scope, timing and costs of existing activities are changed. As of March 31, 2021, the Company estimated a range of possible environmental losses and legal losses of $22,866,000 to $41,313,000. Within the range of possible environmental and legal losses, management has currently concluded that no single amount is more likely to occur than any other amounts in the range and, thus, has accrued at the lower end of the range. These
10
accruals totaled $22,866,000 at March 31, 2021 and $22,884,000 at December 31, 2020. Although the Company believes that its reserves are adequate for contingencies, it is possible due to the uncertainties noted above, that additional reserves could be required in the future. Cash expenditures related to legal matters and environmental matters approximated $280,000 and $912,000 for the three-month periods ended March 31, 2021 and 2020, respectively. Most of the first quarter 2020 cash expenditures related to the Maywood, New Jersey site.
For certain sites, the Company has responded to information requests made by federal, state or local government agencies but has received no response confirming or denying the Company’s stated positions. As such, estimates of the total costs, or range of possible costs, of remediation, if any, or the Company’s share of such costs, if any, cannot be determined with respect to these sites. Consequently, the Company is unable to predict the effect thereof on the Company’s financial position, cash flows and results of operations. Based upon the Company’s present knowledge with respect to its involvement at these sites, the possibility of other viable entities’ responsibilities for cleanup, and the extended period over which any costs would be incurred, management believes that the Company has no material liability at these sites and that these matters, individually and in the aggregate, will not have a material effect on the Company’s financial position. However, in the event of one or more adverse determinations with respect to such sites in any annual or interim period, the effect on the Company’s cash flows and results of operations for those periods could be material.
Following are summaries of the Company’s major contingencies at March 31, 2021:
Maywood, New Jersey Site
The Company’s property in Maywood, New Jersey and property formerly owned by the Company adjacent to its current site and other nearby properties (collectively, the Maywood site) were listed on the National Priorities List in September 1993 pursuant to the provisions of CERCLA because of alleged chemical contamination. Pursuant to (i) a September 21, 1987 Administrative Order on Consent entered into between the U.S. Environmental Protection Agency (USEPA) and the Company for property formerly owned by the Company at the Maywood site and (ii) the issuance of an order on November 12, 2004 by the USEPA to the Company for property currently owned by the Company at the Maywood site, the Company has completed various Remedial Investigation Feasibility Studies (RI/FS), and on September 24, 2014, USEPA issued its Record of Decision (ROD) for chemically-contaminated soil at the Maywood site, which requires the Company to perform remedial cleanup of the soil and buried waste. The USEPA has not yet issued a ROD for chemically-contaminated groundwater at the Maywood site. Based on the most current information available, the Company believes its recorded liability is reasonable having considered the range of estimated costs of remediation for the Maywood site. The estimate of the cost of remediation for the Maywood site could change as the Company continues to hold discussions with the USEPA, as the design of the remedial action is finalized, if a groundwater ROD is issued or if other PRPs are identified. The ultimate amount for which the Company is liable could differ materially from the Company’s current recorded liability.
In April 2015, the Company entered into an Administrative Settlement Agreement and Administrative Order on Consent with USEPA which requires payment of certain costs and performance of certain investigative and design work for chemically-contaminated soil.
In addition, under the terms of a settlement agreement reached on November 12, 2004, the U.S. Department of Justice and the Company agreed to fulfill the terms of a Cooperative Agreement reached in 1985. Under the Cooperative Agreement, the United States is responsible for the removal of radioactive waste at the Maywood site, including past and future remediation costs at the site. As such, the Company recorded no liability related to this settlement agreement.
D’Imperio Property Site
During the mid-1970’s, Jerome Lightman and the Lightman Drum Company disposed of hazardous substances generated by the Company at several sites in New Jersey, including the D’Imperio site. The Company was named as a PRP in an October 2, 1998, lawsuit in the U.S. District Court for the District of New Jersey that involved the D’Imperio Site. In 2020, the PRPs were provided with updated remediation cost estimates by the PRP group technical consultant and project manager, which the Company considered in its determination of its range of estimated possible losses and liability balance. The changes in range of possible losses and liability balance were immaterial. Remediation work continues at the D’Imperio site. Based on current information, the Company believes that its recorded liability is reasonable having considered the range of estimated cost of remediation for the D’Imperio site. Depending on the ultimate cost of the remediation at this site, the amount for which the Company is liable could differ materially from the current estimates.
Wilmington Site
The Company is currently contractually obligated to contribute to the environmental response costs associated with the Company’s formerly-owned site in Wilmington, Massachusetts (the Wilmington site). Remediation at this site is being managed by its current owner to whom the Company sold the property in 1980. Under the Company’s October 1, 1993, agreement with the current owner of the Wilmington site, once total site remediation costs exceed certain levels, the Company is obligated to
11
contribute up to five percent of future response costs associated with this site with no limitation on the ultimate amount of contributions. The Company has paid the current owner $3,078,000 for the Company’s portion of environmental response costs at the Wilmington site through March 31, 2021. The Company has recorded a liability for its portion of the estimated remediation costs for the site. Depending on the ultimate cost of the remediation at this site, the amount for which the Company is liable could differ materially from the current estimates.
The Company and other prior owners of the Wilmington site also entered into an agreement in April 2004 waiving certain statute of limitations defenses for claims which may be filed by the Town of Wilmington, Massachusetts, in connection with this site. While the Company has denied any liability for any such claims, the Company agreed to this waiver while the parties continue to discuss the resolution of any potential claim which may be filed.
Other U.S. Sites
Through the regular environmental monitoring of its plant production sites, the Company discovered levels of chemical contamination that were above thresholds allowed by law at its Millsdale, Illinois and Fieldsboro, New Jersey plants. The Company voluntarily reported its results to the applicable state environmental agencies. As a result, the Company is required to perform self-remediation of the affected areas. Based on current information, the Company believes that its recorded liability for the remediation of the affected areas is appropriate based on an estimate of expected costs. However, actual costs could differ materially from current estimates.
9. |
POSTRETIREMENT BENEFIT PLANS |
Defined Benefit Pension Plans
The Company sponsors various funded qualified and unfunded non-qualified defined benefit pension plans, the most significant of which cover employees in the U.S. and U.K. locations. The U.S. and U.K. defined benefit pension plans are frozen and service benefits are no longer being accrued.
Components of Net Periodic Benefit Cost
|
|
UNITED STATES |
|
|
UNITED KINGDOM |
|
||||||||||
(In thousands) |
|
Three Months Ended March 31 |
|
|
Three Months Ended March 31 |
|
||||||||||
|
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
||||
Interest cost |
|
$ |
1,177 |
|
|
$ |
1,421 |
|
|
$ |
88 |
|
|
$ |
109 |
|
Expected return on plan assets |
|
|
(2,586 |
) |
|
|
(2,437 |
) |
|
|
(81 |
) |
|
|
(134 |
) |
Amortization of net actuarial loss |
|
|
1,144 |
|
|
|
1,052 |
|
|
|
17 |
|
|
|
19 |
|
Net periodic benefit cost |
|
$ |
(265 |
) |
|
$ |
36 |
|
|
$ |
24 |
|
|
$ |
(6 |
) |
Employer Contributions
U.S. Plans
As a result of pension funding relief provisions included in the Highway and Transportation Funding Act of 2014, the Company is not required to make contributions to its funded U.S. qualified defined benefit plans. Approximately $274,000 is expected to be paid related to the unfunded non-qualified plans in 2021. Of such amount, $119,000 had been paid related to the non-qualified plans as of March 31, 2021.
U.K. Plan
The Company’s U.K. subsidiary expects to contribute approximately $495,000 to its defined benefit pension plan in 2021. Of such amount, $141,000 had been contributed to the plan as of March 31, 2021.
Defined Contribution Plans
The Company sponsors retirement savings defined contribution plans that cover eligible U.S. and U.K. employees. The Company’s U.S. retirement plans include two qualified plans, one of which is a 401(k) plan and one of which is an employee stock ownership plan, and one non-qualified supplemental executive plan. In the three months ended March 31, 2021 and 2020, the Company made profit sharing contributions into the qualified retirement plans for U.S. employees and for certain non-U.S. employees. Profit sharing contributions were determined using a formula applied to Company earnings. In 2020 and 2021, profit sharing contributions for U.S. employees were made to the employee stock ownership plan. Profit sharing contributions are allocated to participant accounts based on participant base earnings.
12
Defined contribution plan expenses for the Company’s qualified contribution plans were as follows:
(In thousands) |
|
Three Months Ended March 31 |
|
|||||
|
|
2021 |
|
|
2020 |
|
||
Retirement savings contributions |
|
$ |
2,039 |
|
|
$ |
1,758 |
|
Profit sharing contributions |
|
|
1,866 |
|
|
|
975 |
|
Total defined contribution plan expenses |
|
$ |
3,905 |
|
|
$ |
2,733 |
|
The Company has a rabbi trust to fund the obligations of its non-qualified supplemental executive defined contribution plans (supplemental plans). The trust comprises various mutual fund investments selected by the participants of the supplemental plans. In accordance with the accounting guidance for rabbi trust arrangements, the assets of the trust and the obligations of the supplemental plans are reported on the Company’s condensed consolidated balance sheets. The Company elected the fair value option for the mutual fund investment assets so that offsetting changes in the mutual fund values and defined contribution plan obligations would be recorded in earnings in the same period. Therefore, the mutual funds are reported at fair value with any subsequent changes in fair value recorded in the condensed consolidated statements of income. The liabilities related to the supplemental plans increase (i.e., supplemental plan expense is recognized) when the value of the trust assets appreciates and decrease when the value of the trust assets declines (i.e., supplemental plan income is recognized). At March 31, 2021, the balance of the trust assets was $2,035,000, which equaled the balance of the supplemental plan liabilities (see the long-term investments section in Note 3, Fair Value Measurements, of the notes to the Company’s condensed consolidated financial statements (included in Item 1 of this Form 10-Q) for further information regarding the Company’s mutual fund assets).
10. |
EARNINGS PER SHARE |
Below are the computations of basic and diluted earnings per share for the three months ended March 31, 2021 and 2020:
(In thousands, except per share amounts) |
|
Three Months Ended March 31 |
|
|||||
|
|
2021 |
|
|
2020 |
|
||
Computation of Basic Earnings per Share |
|
|
|
|
|
|
|
|
Net income attributable to Stepan Company |
|
$ |
40,611 |
|
|
$ |
27,545 |
|
Weighted-average number of common shares outstanding |
|
|
22,974 |
|
|
|
23,023 |
|
Basic earnings per share |
|
$ |
1.77 |
|
|
$ |
1.20 |
|
|
|
|
|
|
|
|
|
|
Computation of Diluted Earnings per Share |
|
|
|
|
|
|
|
|
Net income attributable to Stepan Company |
|
$ |
40,611 |
|
|
$ |
27,545 |
|
Weighted-average number of shares outstanding |
|
|
22,974 |
|
|
|
23,023 |
|
Add weighted-average net shares from assumed exercise of options (under treasury stock method) (1) |
|
|
140 |
|
|
|
102 |
|
Add weighted-average net shares related to unvested stock awards (under treasury stock method) |
|
|
1 |
|
|
|
1 |
|
Add weighted-average net shares from assumed exercise of SARs (under treasury stock method) (1) |
|
|
171 |
|
|
|
128 |
|
Add weighted-average contingently issuable net shares related to performance stock awards (under treasury stock method) |
|
|
44 |
|
|
|
31 |
|
Weighted-average shares applicable to diluted earnings |
|
|
23,330 |
|
|
|
23,285 |
|
Diluted earnings per share |
|
$ |
1.74 |
|
|
$ |
1.18 |
|
(1) No options/SARs to acquire shares of Company common stock were excluded from the computation of dilutive earnings per share for the three months ended March 31, 2021. Options/SARs to acquire 256,288 shares of Company common stock were excluded from the computations of diluted earnings per share for the three months ended March 31, 2020. Inclusion of the instruments would have had an antidilutive effect on the computations of the earnings per share.
13
11. |
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) |
Below is the change in the Company’s AOCI balance by component (net of income taxes) for the three months ended March 31, 2021 and 2020:
(In thousands) |
|
Foreign Currency Translation Adjustments |
|
|
Defined Benefit Pension Plan Adjustments |
|
|
Cash Flow Hedge Adjustments |
|
|
Total |
|
||||
Balance at December 31, 2019 |
|
$ |
(104,037 |
) |
|
$ |
(32,205 |
) |
|
$ |
72 |
|
|
$ |
(136,170 |
) |
Other comprehensive income (loss) before reclassifications |
|
|
(41,182 |
) |
|
|
808 |
|
|
|
— |
|
|
|
(40,374 |
) |
Amounts reclassified from AOCI |
|
|
— |
|
|
|
— |
|
|
|
(2 |
) |
|
|
(2 |
) |
Net current-period other comprehensive income (loss) |
|
|
(41,182 |
) |
|
|
808 |
|
|
|
(2 |
) |
|
|
(40,376 |
) |
Balance at March 31, 2020 |
|
$ |
(145,219 |
) |
|
$ |
(31,397 |
) |
|
$ |
70 |
|
|
$ |
(176,546 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2020 |
|
$ |
(107,083 |
) |
|
$ |
(29,861 |
) |
|
$ |
63 |
|
|
$ |
(136,881 |
) |
Other comprehensive income (loss) before reclassifications |
|
|
(18,433 |
) |
|
|
874 |
|
|
|
— |
|
|
|
(17,559 |
) |
Amounts reclassified from AOCI |
|
|
— |
|
|
|
— |
|
|
|
(2 |
) |
|
|
(2 |
) |
Net current-period other comprehensive income (loss) |
|
|
(18,433 |
) |
|
|
874 |
|
|
|
(2 |
) |
|
|
(17,561 |
) |
Balance at March 31, 2021 |
|
$ |
(125,516 |
) |
|
$ |
(28,987 |
) |
|
$ |
61 |
|
|
$ |
(154,442 |
) |
Information regarding the reclassifications out of AOCI for the three-month periods ended March 31, 2021 and 2020, is displayed below:
(In thousands) |
|
Amount Reclassified from AOCI (1) |
|
|||||||
AOCI Components |
|
Three Months Ended March 31 |
|
|
Affected Line Item in Condensed Consolidated Statements of Income |
|||||
|
|
2021 |
|
|
2020 |
|
|
|
||
Amortization of defined benefit pension actuarial losses |
|
$ |
(1,161 |
) |
|
$ |
(1,071 |
) |
|
(2) |
|
|
|
287 |
|
|
|
263 |
|
|
Tax benefit |
|
|
$ |
(874 |
) |
|
$ |
(808 |
) |
|
Net of tax |
Gains and losses on cash flow hedges: |
|
|
|
|
|
|
|
|
|
|
Foreign exchange contracts |
|
|
2 |
|
|
|
2 |
|
|
Cost of sales |
|
|
|
2 |
|
|
|
2 |
|
|
Total before tax |
|
|
|
— |
|
|
|
— |
|
|
Tax benefit |
|
|
$ |
2 |
|
|
$ |
2 |
|
|
Net of tax |
Total reclassifications for the period |
|
$ |
(872 |
) |
|
$ |
(806 |
) |
|
Net of tax |
|
(1) |
Amounts in parentheses denote expense to statement of income. |
|
(2) |
This component of accumulated other comprehensive income is included in the computation of net periodic benefit cost (see Note 9, Postretirement Benefit Plans, of the notes to the Company’s condensed consolidated financial statements (included in Item 1 of this Form 10-Q) for additional details). |
|
14
12. |
SEGMENT REPORTING |
The Company has three reportable segments: Surfactants, Polymers and Specialty Products. Net sales by segment for the three months ended March 31, 2021 and 2020, were as follows:
(In thousands) |
|
Three Months Ended March 31 |
|
|||||
|
|
2021 |
|
|
2020 |
|
||
Segment Net Sales |
|
|
|
|
|
|
|
|
Surfactants |
|
$ |
370,936 |
|
|
$ |
327,071 |
|
Polymers |
|
|
150,385 |
|
|
|
106,491 |
|
Specialty Products |
|
|
16,419 |
|
|
|
16,425 |
|
Total |
|
$ |
537,740 |
|
|
$ |
449,987 |
|
Segment operating income and reconciliations of segment operating income to income before provision for income taxes for the three months ended March 31, 2021 and 2020, are summarized below:
(In thousands) |
|
Three Months Ended March 31 |
|
|||||
|
|
2021 |
|
|
2020 |
|
||
Segment Operating Income |
|
|
|
|
|
|
|
|
Surfactants |
|
$ |
53,210 |
|
|
$ |
36,156 |
|
Polymers |
|
|
17,951 |
|
|
|
7,516 |
|
Specialty Products |
|
|
2,633 |
|
|
|
3,984 |
|
Segment operating income |
|
|
73,794 |
|
|
|
47,656 |
|
Business restructuring |
|
|
(81 |
) |
|
|
(357 |
) |
Unallocated corporate expenses (1) |
|
|
(19,799 |
) |
|
|
(7,295 |
) |
Consolidated operating income |
|
|
53,914 |
|
|
|
40,004 |
|
Interest expense, net |
|
|
(1,524 |
) |
|
|
(1,230 |
) |
Other, net |
|
|
746 |
|
|
|
(3,262 |
) |
Income before provision for income taxes |
|
$ |
53,136 |
|
|
$ |
35,512 |
|
|
(1) |
Unallocated corporate expenses primarily comprise corporate administrative expenses (e.g., corporate finance, legal, human resources, information systems, deferred compensation and environmental remediation) that are not included in segment operating income and are not used to evaluate segment performance. |
|
13. |
REVENUE FROM CONTRACTS WITH CUSTOMERS |
The Company deems a contract with a customer to exist when a purchase order is received from a customer for a specified quantity of product or products and the Company acknowledges receipt of such purchase order. In some instances the Company has entered into manufacturing supply agreements with customers but these agreements typically do not bind a customer to any purchase volume requirements and thus an obligation is not created until the customer submits a purchase order to the Company. The Company’s contracts typically have a single performance obligation that is satisfied at the time a product is shipped and control passes to the customer. For a small portion of the business, performance obligations are deemed satisfied when product is delivered to a customer location.
As of March 31, 2021, the Company had $775,000 of contract liabilities and no contract assets. A contract liability would typically arise when an advance or deposit is received from a customer before the Company recognizes revenue. In practice, this is rare as it would require a customer to make a payment prior to a performance obligation being satisfied. When such situations do arise, the Company would maintain a deferred revenue liability until the time a performance obligation has been satisfied. The Company recognized $773,000 of revenue in the current period from pre-existing contract liabilities at December 31, 2020. During 2020 the Company recognized $10,709,000 of long-term deferred revenue associated with a payment received to defray the cost of capital expenditures necessary to service a customer’s future product needs. This deferred revenue will be recognized over the period of the contract. As of March 31, 2021, no revenue has been recognized from this contract.
15
The tables below provide a geographic disaggregation of net sales for the three months ended March 31, 2021 and 2020. The Company’s business segmentation by geographic region most effectively captures the nature and economic characteristics of the Company’s revenue streams impacted by economic factors.
|
|
For the Three Months Ended March 31, 2021 |
|
|||||||||||||
(In thousands) |
|
|
|
|
|
|
|
|||||||||
|
|
Surfactants |
|
|
Polymers |
|
|
Specialty |
|
|
Total |
|
||||
Geographic Market |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
North America |
|
$ |
220,935 |
|
|
$ |
70,878 |
|
|
$ |
13,937 |
|
|
$ |
305,750 |
|
Europe |
|
|
71,094 |
|
|
|
68,300 |
|
|
|
2,482 |
|
|
|
141,876 |
|
Latin America |
|
|
60,169 |
|
|
|
990 |
|
|
|
— |
|
|
|
61,159 |
|
Asia |
|
|
18,738 |
|
|
|
10,217 |
|
|
|
— |
|
|
|
28,955 |
|
Total |
|
$ |
370,936 |
|
|
$ |
150,385 |
|
|
$ |
16,419 |
|
|
$ |
537,740 |
|
(In thousands) |
|
For the Three Months Ended March 31, 2020 |
|
|||||||||||||
|
|
Surfactants |
|
|
Polymers |
|
|
Specialty |
|
|
Total |
|
||||
Geographic Market |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
North America |
|
$ |
207,946 |
|
|
$ |
61,841 |
|
|
$ |
13,494 |
|
|
$ |
283,281 |
|
Europe |
|
|
59,660 |
|
|
|
36,560 |
|
|
|
2,931 |
|
|
|
99,151 |
|
Latin America |
|
|
46,510 |
|
|
|
639 |
|
|
|
— |
|
|
|
47,149 |
|
Asia |
|
|
12,955 |
|
|
|
7,451 |
|
|
|
— |
|
|
|
20,406 |
|
Total |
|
$ |
327,071 |
|
|
$ |
106,491 |
|
|
$ |
16,425 |
|
|
$ |
449,987 |
|
14. |
DEBT |
Debt was comprised of the following at March 31, 2021, and December 31, 2020:
(In thousands) |
|
Maturity Dates |
|
March 31, 2021 |
|
|
December 31, 2020 |
|
||
Unsecured private placement notes |
|
|
|
|
|
|
|
|
|
|
3.95% (net of unamortized debt issuance cost of $262 and $273 for 2021 and 2020, respectively) |
|
|
|
$ |
99,738 |
|
|
$ |
99,727 |
|
3.86% (net of unamortized debt issuance cost of $222 and $236 for 2021 and 2020, respectively) |
|
|
|
|
71,207 |
|
|
|
71,193 |
|
4.86% (net of unamortized debt issuance cost of $98 and $108 for 2021 and 2020, respectively) |
|
|
|
|
27,759 |
|
|
|
27,749 |
|
Revolving credit facility borrowing |
|
2021 |
|
|
45,000 |
|
|
|
— |
|
Debt of foreign subsidiaries |
|
|
|
|
|
|
|
|
|
|
Unsecured bank debt, foreign currency |
|
2021 |
|
|
4,668 |
|
|
|
— |
|
Total debt |
|
|
|
$ |
248,372 |
|
|
$ |
198,669 |
|
Less current maturities |
|
|
|
|
87,525 |
|
|
|
37,857 |
|
Long-term debt |
|
|
|
$ |
160,847 |
|
|
$ |
160,812 |
|
The Company has a committed $350,000,000 multi-currency revolving credit agreement that expires on January 30, 2023. The Company maintains import letters of credit, and standby letters of credit under its workers’ compensation insurance agreements and for other purposes, as needed from time to time, which are issued under the revolving credit agreement. As of March 31, 2021, the Company had outstanding borrowing totaling $45,000,000 with the weighted average interest rate of 1.36 percent and outstanding letters of credit totaling $6,767,000. There was $298,233,000 available under the revolving credit agreement as of March 31, 2021.
The Company’s loan agreements contain provisions which, among others, require maintenance of certain financial ratios and place limitations on additional debt, investments and payment of dividends. Based on the loan agreement provisions that place limitations on dividend payments, unrestricted retained earnings (i.e., retained earnings available for dividend distribution) were $407,026,000 and $373,884,000 at March 31, 2021 and December 31, 2020, respectively.
16
15. |
OTHER, NET |
Other, net in the condensed consolidated statements of income included the following:
(In thousands) |
|
Three Months Ended March 31 |
|
|||||
|
|
2021 |
|
|
2020 |
|
||
Foreign exchange (losses) gains |
|
$ |
(335 |
) |
|
$ |
568 |
|
Investment income |
|
|
306 |
|
|
|
75 |
|
Realized and unrealized gains (losses) on investments |
|
|
534 |
|
|
|
(3,875 |
) |
Net periodic pension benefit |
|
|
241 |
|
|
|
(30 |
) |
Other, net |
|
$ |
746 |
|
|
$ |
(3,262 |
) |
|
|
|
|
|
|
|
|
|
16. |
BUSINESS RESTRUCTURING |
2018 Restructuring
During the third quarter of 2018, the Company approved a plan to shut down Surfactant operations at its German plant site. As of March 31, 2020, an aggregate of $2,392,000 shut down related expense has been recognized at the site. In the first quarter of 2020, the Company recognized $79,000 of decommissioning expenses at the site. The Company finalized shut down of the plant in 2020 and no more expenses associated with the restructuring are expected.
2016 Restructuring
During 2016, the Company shut down its Longford Mills, Ontario, Canada (Longford Mills) manufacturing facility, a part of the Surfactant reportable segment. The shutdown plan was implemented to improve the Company’s asset utilization in North America and to reduce the Company’s fixed cost base. Manufacturing operations of the Longford Mills plant ceased by the end of 2016, and production of goods manufactured at the facility was transferred to other Company North American production sites. Decommissioning of the assets is expected to continue throughout 2021. As of March 31, 2021, $8,698,000 of aggregate restructuring expense has been recognized, reflecting $1,644,000 of termination benefits for approximately 30 employees and $7,054,000 for other expenses, principally site decommissioning costs. The Company recognized $81,000 and $278,000 of decommissioning expenses in the first quarter of 2021 and 2020, respectively.
17
17. |
ACQUISITIONS |
2021 Acquisitions
INVISTA Acquisition
On January 29, 2021, the Company and its wholly-owned subsidiaries Stepan Holdings Netherlands B.V. and Stepan UK Limited (collectively, “Stepan”) entered into a Stock and Asset Purchase Agreement with Arteva Specialties B.V., INV Performance Surfaces, LLC, INVISTA Textiles (U.K.) Limited, INV Management Services, LLC, and INVISTA Equities, LLC (collectively, “INVISTA”) to acquire INVISTA's aromatic polyester polyol business and associated assets. Included in the transaction were two manufacturing sites, one in Wilmington, North Carolina (U.S.) and the other in Vlissingen, Netherlands, along with intellectual property, customer relationships, inventory and working capital. This acquisition expands the Company’s manufacturing capabilities in both the United States and Europe and enhances its business continuity capabilities for the market. The Company believes that INVISTA’s available spare capacity, combined with debottlenecking opportunities for both plants, will allow Stepan to support future market growth in a capital efficient way. The purchase price was $165,000,000, plus $21,000,000 of estimated working capital and $3,000,000 of associated value-added taxes (VAT) and was paid in cash. The working capital acquired included $5,000,000 of cash. The acquisition has been accounted for as a business combination, and the acquired operations are included in the Company’s Polymer segment in the first quarter of 2021. The assets acquired and liabilities assumed as part of the acquisition were measured and recorded at estimated fair value. The purchase price allocation remains preliminary as of March 31, 2021 pending finalization of the fair value of intangibles and property, plant and equipment. The principle valuation techniques employed include cost and market approaches (PP&E), relief from royalty method under the income approach (trade name and technology/know) and multi-period excess earnings method under the income approach (customer relationships). The following table summarizes the preliminary purchase price allocation for the major components of the acquisition:
(In thousands) |
|
|
|
|
Assets: |
|
|
|
|
Property, plant and equipment |
|
$ |
54,400 |
|
Identifiable intangible assets |
|
|
45,500 |
|
Goodwill |
|
|
65,100 |
|
Total assets acquired |
|
$ |
165,000 |
|
The acquired goodwill includes proprietary and intellectual property, brand recognition, business continuity benefits and marketing, manufacturing and supply chain synergies of the new business with the Company’s existing Polymer business. The acquired goodwill has been assigned to the Polymers segment and is deductible for tax purposes. Identifiable intangible assets included technology and manufacturing know-how ($13,000,000), trademarks ($8,000,000) and customer relationships ($24,500,000). The amortization periods for know-how and trademarks has initially been estimated to be in the range of 7 to 8 years. The amortization period for customer relationships has initially been estimated to be in the range of 12 to 14 years. As of March 31, 2021, in addition to the purchase price, the Company also paid $3,232,000 of acquisition-related expenses that included legal, consulting, valuation and accounting services. During the first three months of 2021, the Company incurred $1,285,000 of acquisition-related expenses. These costs were included in the Administrative expenses line in the Company’s condensed consolidated statement of income.
The following table reflects pro forma financial information prepared under the assumption that the acquisition of the INVISTA aromatic polyester polyol business occurred on January 1, 2020.
Pro Forma Financial Information
Unaudited
|
|
Three Months Ended March 31 |
|
|||||
(In thousands, except per share amounts) |
|
2021 |
|
|
2020 |
|
||
Net Sales |
|
$ |
550,179 |
|
|
$ |
475,887 |
|
Net Income Attributable to Stepan Company |
|
$ |
43,112 |
|
|
$ |
28,602 |
|
The supplemental pro forma information is presented for illustrative purposes only and may not be indicative of the consolidated results that would have actually been achieved by the Company. Furthermore, future results may vary significantly from the results reflected in the pro forma information. The pro forma results include adjustments primarily related to amortization of acquired intangible assets, depreciation of the fair value adjustment of acquisition-date plant assets, and tax expense. In addition, non-recurring adjustments to pro forma net income include $1,285,000 of acquisition-related expenses - such expenses were excluded from 2021 pro forma net income and included in 2020 pro forma net income.
18
Fermentation Plant Acquisition
On February 2, 2021, the Company acquired a fermentation plant, located in Lake Providence, Louisiana (U.S.). The Company believes this plant complements the rhamnolipid-based bio-surfactant technology the Company acquired from Logos Technologies in March 2020. Fermentation is a new platform technology for the Company and the Company is focusing efforts to further develop, integrate, produce and commercialize these unique surfactants moving forward. Bio-surfactants, produced via fermentation, are attractive due to their biodegradability, low toxicity, and in some cases, unique antimicrobial properties. These bio-surfactants offer synergies in several strategic end use markets including oilfield, agriculture, personal care and household, industrial and institutional. The acquisition of this industrial scale fermentation plant represents the latest step in the Company’s bio-surfactant commercialization efforts. The purchase price was $3,500,000 and was paid in cash. This acquisition has been accounted for as an asset acquisition.
2020 Acquisitions
Clariant (Mexico) Acquisition
On September 17, 2020, the Company through its subsidiaries in Mexico, acquired Clariant (Mexico) S.A. de C.V.’s (Clariant) anionic business located in Santa Clara, Mexico. The acquisition did not include the purchase of a manufacturing site. The business acquired was integrated into the Company’s two existing manufacturing sites in Mexico (Matamoros and Ecatepec). The purchase price of the acquisition was $14,000,000, plus associated value-added taxes (VAT). As of March 31, 2021, $13,519,000, inclusive of $308,000 net VAT, had been paid with cash on hand. The acquisition was accounted for as a business combination and the assets were measured and recorded at their estimated fair value. The acquired goodwill is not tax deductible. All assets acquired are included in the Company’s Surfactants segment. The following table summarizes the purchase price allocation for the acquisition:
(In thousands) |
|
|
|
|
Assets: |
|
|
|
|
Identifiable intangible assets: |
|
|
|
|
Customer lists |
|
$ |
8,000 |
|
Trademarks and know-how |
|
|
1,300 |
|
Non-compete agreement |
|
|
300 |
|
Goodwill |
|
|
4,225 |
|
Property, plant and equipment |
|
|
175 |
|
Total assets acquired |
|
$ |
14,000 |
|
Logos Technologies Acquisition
On March 13, 2020, the Company acquired certain assets of Logos Technologies LLC's NatSurFact® business, a rhamnolipid-based line of bio-surfactants derived from renewable sources. These bio-surfactants offer synergies in several strategic end use markets including oilfield, agriculture, personal care and household, industrial and institutional. The acquisition was accounted for as an asset acquisition. The purchase price of the acquisition was $2,040,000 and was paid with cash on hand. All assets acquired are included in the Company’s Surfactants segment. The assets acquired were primarily intangibles, including trademarks and know-how ($1,392,000) and patents ($464,000). Additionally, $184,000 of laboratory equipment was acquired.
18. |
RECENT ACCOUNTING PRONOUNCEMENTS |
In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740), Simplifying the Accounting for Income Taxes. This update provides guidance to reduce complexity in certain areas of accounting for income taxes. The amendments in this update are effective for fiscal years beginning after December 15, 2020. The Company adopted ASU. No. 2019-12 in the first quarter of 2021 and the adoption of this update did not have a material effect on the Company’s financial position, results of operations and cash flows.
In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848) Facilitation of the Effect of Reference Rate Reform on Financial Reporting. This update provides optional guidance for a limited period of time to ease the burden of implementing the usage of new reference rates. The amendments apply to contract modifications that replace a reference rate affected by reference rate reform and contemporaneous modifications of other contract terms related to the replacement of the reference rate. If elected the optional expedients to contract modifications must be applied consistently for all eligible contracts or eligible transactions. The amendments in this update may be implemented between March 12, 2020 and December 31, 2022. The guidance should be applied prospectively. The Company has not utilized any of the optional expedients of exceptions available under this ASU. The Company will continue to assess whether this ASU is applicable throughout the effective period.
19
Item 2 - Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following is management’s discussion and analysis (MD&A) of certain significant factors that have affected the Company’s financial condition and results of operations during the interim periods included in the accompanying condensed consolidated financial statements.
Certain statements in this Quarterly Report on Form 10-Q, other than purely historical information, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). These statements include statements about Stepan Company’s and its subsidiaries’ (the Company) plans, objectives, strategies, financial performance and outlook, trends, the amount and timing of future cash distributions, prospects or future events and involve known and unknown risks that are difficult to predict. As a result, the Company’s actual financial results, performance, achievements or prospects may differ materially from those expressed or implied by these forward-looking statements. In some cases, forward-looking statements can be identified by the use of words such as “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “guidance,” “predict,” “potential,” “continue,” “likely,” “will,” “would,” “should,” “illustrative” and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by the Company and its management based on their knowledge and understanding of the business and industry, are inherently uncertain. These statements are not guarantees of future performance, and stockholders should not place undue reliance on forward-looking statements. There are a number of risks, uncertainties and other important factors, many of which are beyond the Company’s control, that could cause the Company’s actual results to differ materially from the forward-looking statements contained in this Quarterly Report on Form 10-Q.
Such risks, uncertainties and other important factors, include, among others, the risks, uncertainties and factors set forth under “Part II-Item IA - Risk Factors” of this Quarterly Report on Form 10-Q and under “Part I-Item IA. Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, including the risks and uncertainties related to the following:
|
• |
the impact of the COVID-19 pandemic; |
|
• |
accidents, unplanned production shutdowns or disruptions in any of the Company’s manufacturing facilities; |
|
• |
reduced demand for Company products due to customer product reformulations or new technologies; |
|
• |
the Company’s inability to successfully develop or introduce new products; |
|
• |
compliance with environmental, health and safety, product registration and anti-corruption laws; |
|
• |
the Company’s ability to make acquisitions of suitable candidates and successfully integrate acquisitions; |
|
• |
global competition and the Company’s ability to successfully compete; |
|
• |
volatility of raw material, natural gas and electricity costs as well as any disruption in their supply; |
|
• |
disruptions in transportation or significant changes in transportation costs; |
|
• |
downturns in certain industries and general economic downturns; |
|
• |
international business risks, including fluctuations in currency exchange rates, legal restrictions and taxes; |
|
• |
unfavorable resolution of litigation against the Company; |
|
• |
the Company’s ability to keep and protect its intellectual property rights; |
|
• |
potentially adverse tax consequences due to the international scope of the Company’s operations; |
|
• |
downgrades to the Company’s credit ratings or disruptions to the Company’s ability to access well-functioning capital markets; |
|
• |
conflicts, military actions, terrorist attacks and general instability, particularly in certain energy-producing nations, along with increased security regulations; |
|
• |
cost overruns, delays and miscalculations in capacity needs with respect to the Company’s expansion or other capital projects; |
|
• |
interruption of, damage to or compromise of the Company’s IT systems and failure to maintain the integrity of customer, colleague or Company data; |
|
• |
the Company’s ability to retain its executive management and other key personnel; |
|
• |
the Company’s ability to operate within the limitations of debt covenants; and |
|
• |
the other factors set forth under “Risk Factors.” |
20
These factors are not necessarily all of the important factors that could cause the Company’s actual financial results, performance, achievements or prospects to differ materially from those expressed in or implied by any of its forward-looking statements. Other unknown or unpredictable factors also could harm the Company’s results. All forward-looking statements attributable to the Company or persons acting on the Company’s behalf are expressly qualified in their entirety by the cautionary statements set forth above. Forward-looking statements speak only as of the date they are made, and the Company does not undertake or assume any obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If the Company updates one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect to those or other forward-looking statements.
The “Company,” “we,” “our” or “us” means Stepan Company and one or more of its subsidiaries only.
Overview
The Company produces and sells intermediate chemicals that are used in a wide variety of applications worldwide. The overall business comprises three reportable segments:
Surfactants – Surfactants, which accounted for 69 percent of Company consolidated net sales for the first three months of 2021
are principal ingredients in consumer and industrial cleaning and disinfection products such as detergents for washing clothes, dishes, carpets, floors and walls, as well as shampoos and body washes. Other applications include fabric softeners, germicidal quaternary compounds, disinfectants, lubricating ingredients, emulsifiers for spreading agricultural products and industrial applications such as latex systems, plastics and composites. Surfactants are manufactured at five sites in the United States, two European sites (United Kingdom and France), five Latin American sites (one site in Colombia and two sites in each of Mexico and Brazil) and two Asian sites (Philippines and Singapore). Recent significant events include:
|
o |
On January 19, 2020, the Company experienced a power disruption that impacted its Millsdale, Illinois facility. This power outage combined with below freezing temperatures led to significant production and operational challenges that impacted both Surfactants and Polymers produced at the site. The Millsdale facility operated on a partial basis and used existing inventories to serve the Company’s customers. However, on February 17, 2020, power outage-related operational issues impacted the Millsdale site’s waste water treatment plant (WWTP) and forced the Company to stop production at the site. As a result, the Company declared force majeure for the supply of phthalic anhydride (Polymers) and certain surfactant product lines. All production lines were fully operational prior to the end of the first quarter of 2020. The Company finalized an insurance settlement related to this power outage in the second half of 2020. |
|
o |
In March 2020, the Company acquired certain assets of Logos Technologies LLC's NatSurFact® business, a rhamnolipid-based line of bio-surfactants derived from renewable sources. These bio-surfactants offer synergies in several strategic end use markets including oilfield, agriculture, personal care and household, industrial and institutional. The Company has focused its efforts to further develop, integrate and commercialize these unique surfactants moving forward. The Company believes the rhamnolipid technology will further advance the growth and sustainability aspirations of both the Company and its customers. (See Note 17, Acquisitions, of the notes to the Company’s condensed consolidated financial statements (included in Item 1 of this Form 10-Q) for additional details). |
|
o |
In September 2020, the Company, through its subsidiaries in Mexico, acquired Clariant’s anionic surfactant business located in Santa Clara, Mexico. The acquisition did not include the purchase of a manufacturing site. The business acquired was integrated into the Company’s two existing manufacturing sites in Mexico (Matamoros and Ecatepec). This acquisition supports the Company’s growth strategy in Latin America and the Company believes the acquisition enhances its ability to support customer growth in the Mexican consumer and functional surfactant markets. |
|
o |
In February 2021, the Company acquired a fermentation plant located in Lake Providence, Louisiana. The Company believes this plant complements the rhamnolipid-based bio-surfactant technology the Company acquired from Logos Technologies in March 2020. Fermentation is a new platform technology for the Company and the Company is focusing efforts to further develop, integrate, produce and commercialize these unique surfactants moving forward. Bio-surfactants, produced via fermentation, are attractive due to their biodegradability, low toxicity, and in some cases, unique antimicrobial properties. These bio-surfactants offer synergies in several strategic end use markets including oilfield, agriculture, personal care and household, industrial and institutional. The acquisition of this industrial scale fermentation plant represents the latest step in the Company’s bio-surfactant commercialization efforts (see Note 17, Acquisitions, of the notes to the Company’s condensed consolidated financial statements (included in Item 1 of this Form 10-Q) for additional details). |
21
o |
Polymers – Polymers, which accounted for 28 percent of consolidated net sales for the first three months of 2021, include polyurethane polyols, polyester resins and phthalic anhydride. Polyurethane polyols are used in the manufacture of rigid foam for thermal insulation in the construction industry and are also a base raw material for coatings, adhesives, sealants and elastomers (collectively, CASE products). Powdered polyester resins are used in coating applications. CASE and powdered polyester resins are collectively referred to as specialty polyols. Phthalic anhydride is used in unsaturated polyester resins, alkyd resins and plasticizers for applications in construction materials and components of automotive, boating and other consumer products. In addition, the Company uses phthalic anhydride internally in the production of polyols. In the United States, polyurethane polyols are manufactured at the Company’s Millsdale, Illinois, and Wilmington, North Carolina sites (see INVISTA acquisition discussion below). Phthalic anhydride is manufactured at the Company’s Millsdale, Illinois site and specialty polyols are manufactured at the Company’s Columbus, Georgia, site. In Europe, polyurethane polyols are manufactured by the Company’s subsidiary in Germany and Vlissingen, Netherlands (see INVISTA acquisition discussion below) and specialty polyols are manufactured by the Company’s Poland subsidiary. In China, polyurethane polyols and specialty polyols are manufactured at the Company’s Nanjing, China, plant. Recent significant events include: |
|
o |
The operational issues at the Company’s Millsdale, Illinois facility, described in the Surfactants significant events paragraph above, negatively impacted Polymers earnings during the first quarter of 2020. |
|
o |
In January 2021, the Company purchased INVISTA’s aromatic polyester polyol business and associated assets. Included in the transaction were two manufacturing sites, one in Wilmington, North Carolina and the other in Vlissingen, Netherlands, along with intellectual property, customer relationships, inventory and working capital. This acquisition expands the Company’s manufacturing capabilities in both the United States and Europe and enhances the Company’s business continuity capabilities for the market. The Company believes that INVISTA’s available spare capacity, combined with debottlenecking opportunities in both plants, will allow Stepan to support future market growth in a capital efficient way (see Note 17, Acquisitions, of the notes to the Company’s condensed consolidated financial statements (included in Item 1 of this Form 10-Q) for additional details). |
Specialty Products – Specialty products, which accounted for three percent of consolidated net sales for the first three months of 2021, include flavors, emulsifiers and solubilizers used in food, flavoring, nutritional supplement and pharmaceutical applications. Specialty products are primarily manufactured at the Company’s Maywood, New Jersey, site and, in some instances, by third-party contractors.
2021 Acquisitions
In January 2021, the Company purchased INVISTA’s aromatic polyester polyol business and associated assets. Included in the transaction were two manufacturing sites, one in Wilmington, North Carolina and the other in Vlissingen, Netherlands along with intellectual property, customer relationships, inventory and working capital. This acquisition expands the Company’s manufacturing capabilities in both the United States and Europe and enhances the Company’s business continuity capabilities for the market. The Company believes that INVISTA’s available spare capacity, combined with debottlenecking opportunities in both plants, will allow Stepan to support future market growth in a capital efficient way. This acquisition was accounted for as a business combination, and accordingly, the assets acquired were measured and recorded at their preliminary fair values. The purchase price of the acquisition was $165.0 million, plus $21.0 million of estimated working capital and $3.0 million of associated value-added taxes (VAT). The working capital acquired included $5.0 million of cash. The acquisition was paid with cash on hand. (See Note 17, Acquisitions, of the notes to the Company’s condensed consolidated financial statements (included in Item 1 of this Form 10-Q) for additional details).
In February 2021, the Company acquired a fermentation plant located in Lake Providence, Louisiana. The Company believes this plant complements the rhamnolipid-based bio-surfactant technology the Company acquired from Logos Technologies in March 2020. Fermentation is a new platform technology for the Company and the Company is focusing efforts to further develop, integrate, produce and commercialize these unique surfactants moving forward. Bio-surfactants, produced via fermentation, are attractive due to their biodegradability, low toxicity, and in some cases, unique antimicrobial properties. These bio-surfactants offer synergies in several strategic end use markets including oilfield, agriculture, personal care and household, industrial and institutional. The acquisition of this industrial scale fermentation plant represents the latest step in the Company’s bio-surfactant commercialization efforts. This acquisition was accounted for as an asset acquisition. The purchase price of the acquisition was $3.5 million and was paid with cash on hand. (See Note 17, Acquisitions, of the notes to the Company’s condensed consolidated financial statements (included in Item 1 of this Form 10-Q) for additional details).
Deferred Compensation Plans
The accounting for the Company’s deferred compensation plans can cause period-to-period fluctuations in Company expenses and profits. Compensation expense results when the values of Company common stock and mutual fund investment assets held for the
22
plans increase, and compensation income results when the values of Company common stock and mutual fund investment assets decline. The pretax effect of all deferred compensation-related activities (including realized and unrealized gains and losses on the mutual fund assets held to fund the deferred compensation obligations) and the income statement line items in which the effects of the activities were recorded are displayed in the following table:
|
|
Income (Expense) |
|
|
|
|
|
|
|||||
|
|
For the Three Months Ended March 31 |
|
|
|
|
|
|
|||||
(In millions) |
|
2021 |
|
|
2020 |
|
|
Change |
|
|
|||
Deferred Compensation (Administrative expense) |
|
$ |
(2.7 |
) |
|
$ |
7.3 |
|
|
$ |
(10.0 |
) |
|
Realized/Unrealized Gains on Investments (Other, net) |
|
|
0.4 |
|
|
|
(3.6 |
) |
|
|
4.0 |
|
|
Investment Income (Other, net) |
|
|
0.3 |
|
|
|
0.1 |
|
|
|
0.2 |
|
|
Pretax Income Effect |
|
$ |
(2.0 |
) |
|
$ |
3.8 |
|
|
$ |
(5.8 |
) |
|
Effects of Foreign Currency Translation
The Company’s foreign subsidiaries transact business and report financial results in their respective local currencies. As a result, foreign subsidiary income statements are translated into U.S. dollars at average foreign exchange rates appropriate for the reporting period. Because foreign exchange rates fluctuate against the U.S. dollar over time, foreign currency translation affects period-to-period comparisons of financial statement items (i.e., because foreign exchange rates fluctuate, similar period-to-period local currency results for a foreign subsidiary may translate into different U.S. dollar results). The following table presents the effects that foreign currency translation had on the period-over-period changes in consolidated net sales and various income statement line items for the three months ended March 31, 2021 and 2020:
|
|
Three Months Ended March 31 |
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Increase |
|
|
(In millions) |
|
2021 |
|
|
2020 |
|
|
Increase |
|
|
Due to Foreign Translation |
|
||||
Net Sales |
|
$ |
537.7 |
|
|
$ |
450.0 |
|
|
$ |
87.7 |
|
|
$ |
4.2 |
|
Gross Profit |
|
|
109.0 |
|
|
|
79.3 |
|
|
|
29.7 |
|
|
|
0.2 |
|
Operating Income |
|
|
53.9 |
|
|
|
40.0 |
|
|
|
13.9 |
|
|
|
0.0 |
|
Pretax Income |
|
|
53.1 |
|
|
|
35.5 |
|
|
|
17.6 |
|
|
|
0.0 |
|
RESULTS OF OPERATIONS
Three Months Ended March 31, 2021 and 2020
Summary
Net income attributable to the Company for the first quarter of 2021 increased 47 percent to $40.6 million, or $1.74 per diluted share, from $27.5 million, or $1.18 per diluted share, for the first quarter of 2020. Adjusted net income increased 75 percent to $42.4 million, or $1.82 per diluted share, from $24.2 million, or $1.04 per diluted share in 2020 (see the “Reconciliation of Non-GAAP Adjusted Net Income and Diluted Earnings per Share” section of this MD&A for a reconciliation between reported net income attributable to the Company and reported earnings per diluted share and non-GAAP adjusted net income and adjusted earnings per diluted share). Below is a summary discussion of the major factors leading to the changes in net sales, expenses and income in the first quarter of 2021 compared to the first quarter of 2020. A detailed discussion of segment operating performance for the first quarter of 2021 compared to the first quarter of 2020 follows the summary.
Consolidated net sales increased $87.8 million, or 20 percent, between quarters. Higher average selling prices favorably impacted the year-over-year change in net sales by $55.0 million. The increase in average selling prices was mainly attributable to improved product and customer mix and the pass-through of higher raw material costs. Consolidated sales volume increased six percent, which had a $28.6 million favorable impact on the year-over-year change in net sales. Sales volume in the Polymer and Specialty Products segments increased 32 percent and four percent, respectively. The increase in Polymers sales volume reflects a gradual recovery from COVID-19 delays and cancellations of re-roofing and new construction projects, the 2021 acquisition of INVISTA’s aromatic polyester polyol business, and the non-recurrence of the plant power outage at the Company’s Millsdale, Illinois facility in the first quarter of 2020. Sales volume for the Surfactant segment was flat between quarters. Higher Surfactant sales volume in Europe, Latin America, and Asia was offset by lower North American sales volume. North American sales volume was negatively impacted by supply chain disruptions caused by the severe weather in Texas. Foreign currency translation favorably impacted the year-over-year change in net sales by $4.2 million primarily due to a strengthening of European currencies versus the U.S. dollar.
23
Operating income for the first quarter of 2021 increased $13.9 million, or 35 percent, versus operating income for the first quarter of 2020. Surfactant and Polymer operating income increased $17.1 million and $10.4 million, respectively. Specialty Products operating income decreased $1.4 million. Corporate expenses, including business restructuring and deferred compensation expenses, increased $12.2 million year-over-year. Deferred compensation expenses increased $10.0 million while business restructuring expenses declined $0.3 million. Corporate expenses (excluding deferred compensation and business restructuring expenses) increased $2.5 million mostly due to higher acquisition-related costs and incentive-based compensation expenses. The impact of foreign currency translation on operating income was negligible between quarters.
Operating expenses (including deferred compensation and business restructuring expense) increased $15.8 million, or 40 percent, between quarters. Changes in the individual income statement line items that comprise the Company’s operating expenses were as follows:
|
• |
Selling expenses increased $1.0 million, or seven percent, year-over-year. Most of this increase reflects higher salaries and incentive-based compensation expenses in 2021. |
|
• |
Administrative expenses increased $3.8 million, or 20 percent, year-over-year. This increase is primarily due to higher acquisition-related costs and incentive-based compensation expenses in 2021. |
|
• |
Research, development and technical service (R&D) expenses increased $1.3 million, or 10 percent, year-over-year. Most of this increase reflects higher salaries and incentive-based compensation expenses in 2021. |
|
• |
Deferred compensation expense increased $10 million, year-over-year, primarily due to a $7.79 per share increase in the market price of Company common stock in the first quarter of 2021 compared to a $13.98 per share decrease in the first quarter of 2020. See the Overview and Segment Results-Corporate Expenses section of this MD&A for further details. |
|
• |
Business restructuring expenses totaled $0.1 million in the first quarter of 2021 versus $0.4 million in the first quarter of 2020. The 2021 business restructuring charges reflect ongoing decommissioning costs associated with the Company’s manufacturing facility in Canada. The 2020 restructuring expenses were comprised of decommissioning costs associated with the Company’s manufacturing facility in Canada ($0.3 million) and decommissioning costs associated with Company’s sulfonation shut down in Germany ($0.1 million). |
Net interest expense for the first quarter of 2021 increased $0.3 million, or 24 percent, versus the first quarter of 2020. This increase was primarily attributable to lower interest income resulting from lower interest rates due to global market conditions. Partially offsetting the above was lower interest expense resulting from scheduled debt repayments.
Other, net was $0.7 million of income in the first quarter of 2021 versus $3.3 million of expense in the first quarter of 2020. The Company recognized $0.8 million of investment income (including realized and unrealized gains and losses) for the Company’s deferred compensation and supplemental defined contribution mutual fund assets in the first quarter of 2021 compared to $3.8 million of investment losses in last year’s first quarter. In addition, the Company reported $0.3 million of foreign exchange losses in the first quarter of 2021 versus $0.6 million of foreign exchange gains in the first quarter of 2020. The Company also reported $0.3 million of lower net periodic pension cost benefits in the first quarter of 2021 versus the prior year first quarter.
The Company’s effective tax rate was 23.6 percent in the first quarter of 2021 versus 22.5 percent in the first quarter of 2020. The year-over-year increase was primarily attributable to a less favorable geographical mix of income in 2021 that was partially offset by higher tax benefits derived from stock-based compensation awards exercised or distributed in the first quarter of 2021 versus the first quarter of 2020.
Segment Results
|
|
For the Three Months Ended |
|
|
|
|
|
|
|
|
|
|||||
(Dollars in thousands) |
|
March 31, |
|
|
March 31, |
|
|
|
|
|
|
Percent |
|
|||
Net Sales |
|
2021 |
|
|
2020 |
|
|
Increase (Decrease) |
|
|
Change |
|
||||
Surfactants |
|
$ |
370,936 |
|
|
$ |
327,071 |
|
|
$ |
43,865 |
|
|
|
13 |
|
Polymers |
|
|
150,385 |
|
|
|
106,491 |
|
|
|
43,894 |
|
|
|
41 |
|
Specialty Products |
|
|
16,419 |
|
|
|
16,425 |
|
|
|
(6 |
) |
|
|
0 |
|
Total Net Sales |
|
$ |
537,740 |
|
|
$ |
449,987 |
|
|
$ |
87,753 |
|
|
|
20 |
|
24
|
|
For the Three Months Ended |
|
|
|
|
|
|
|
|
|
|||||
(Dollars in thousands) |
|
March 31, |
|
|
March 31, |
|
|
Increase |
|
|
Percent |
|
||||
Operating Income |
|
2021 |
|
|
2020 |
|
|
(Decrease) |
|
|
Change |
|
||||
Surfactants |
|
$ |
53,210 |
|
|
$ |
36,156 |
|
|
$ |
17,054 |
|
|
|
47 |
|
Polymers |
|
|
17,951 |
|
|
|
7,516 |
|
|
|
10,435 |
|
|
|
139 |
|
Specialty Products |
|
|
2,633 |
|
|
|
3,984 |
|
|
|
(1,351 |
) |
|
|
-34 |
|
Segment Operating Income |
|
$ |
73,794 |
|
|
$ |
47,656 |
|
|
$ |
26,138 |
|
|
|
55 |
|
Corporate Expenses, Excluding Deferred Compensation and Restructuring |
|
|
17,105 |
|
|
|
14,618 |
|
|
|
2,487 |
|
|
|
17 |
|
Deferred Compensation Expense |
|
|
2,694 |
|
|
|
(7,323 |
) |
|
|
10,017 |
|
|
|
-137 |
|
Business Restructuring |
|
|
81 |
|
|
|
357 |
|
|
|
(276 |
) |
|
|
-77 |
|
Total Operating Income |
|
$ |
53,914 |
|
|
$ |
40,004 |
|
|
$ |
13,910 |
|
|
|
35 |
|
Surfactants
Surfactant net sales for the first quarter of 2021 increased $43.9 million, or 13 percent, versus net sales for the first quarter of 2020. Higher average selling prices and the favorable impact of foreign currency translation positively impacted the change in net sales by $42.5 million and $1.5 million, respectively. The higher average selling prices were mainly attributable to improved product and customer mix and the pass-through of higher raw material costs. Sales volume was essentially flat year-over-year and negatively impacted the change in net sales by $0.1 million. Higher sales volume in Europe, Latin American and Asia was offset by lower sales volume in North America due to supply chain disruptions caused by the severe weather in Texas. A comparison of net sales by region follows:
|
|
For the Three Months Ended |
|
|
|
|
|
|
|
|
|
|||||
(Dollars in thousands) |
|
March 31, |
|
|
March 31, |
|
|
|
|
|
|
Percent |
|
|||
Net Sales |
|
2021 |
|
|
2020 |
|
|
Increase |
|
|
Change |
|
||||
North America |
|
$ |
220,935 |
|
|
$ |
207,946 |
|
|
$ |
12,989 |
|
|
|
6 |
|
Europe |
|
|
71,094 |
|
|
|
59,660 |
|
|
|
11,434 |
|
|
|
19 |
|
Latin America |
|
|
60,169 |
|
|
|
46,510 |
|
|
|
13,659 |
|
|
|
29 |
|
Asia |
|
|
18,738 |
|
|
|
12,955 |
|
|
|
5,783 |
|
|
|
45 |
|
Total Surfactants Segment |
|
$ |
370,936 |
|
|
$ |
327,071 |
|
|
$ |
43,865 |
|
|
|
13 |
|
Net sales for North American operations increased $13.0 million, or six percent, year over year. Higher average selling prices and the favorable impact of foreign currency translation positively impacted the change in net sales by $22.3 million and $0.5 million, respectively. The higher average selling prices were mainly attributable to improved product and customer mix and the pass-through of higher raw material costs. Sales volume declined five percent and negatively impacted the year-over-year change in net sales by $9.8 million. Higher customer demand for products sold into the agricultural and oilfield end markets was more than offset by lower volume of products sold into the consumer product end markets due to supply chain disruptions caused by the severe weather in Texas.
Net sales for European operations increased $11.4 million, or 19 percent, year-over-year. The favorable impact of foreign currency translation, higher average selling prices and a one percent increase in sales volume positively impacted the year-over-year change in net sale by $5.7 million, $5.1 million and $0.6 million, respectively. Higher average selling prices are primarily due to pass-through of higher raw material costs. A weaker U.S. dollar relative to the European euro and British pound sterling led to the favorable foreign currency translation effect. The increase in sales volume was primarily due to increased demand for cleaning and disinfection products that was partially offset by lower demand for products sold to our distribution partners.
Net sales for Latin American operations increased $13.7 million, or 29 percent, primarily due higher average selling prices and an eight percent increase in sales volume. These items positively impacted the change in net sales by $15.4 million and $3.8 million, respectively. The sales volume growth was mostly due to higher demand for products sold into the consumer products and agricultural end markets. Partially offsetting the above was the unfavorable impact of foreign currency translation which negatively impacted the change in net sales by $5.6 million. A stronger U.S. dollar relative to the Brazilian real and Mexican peso led to the unfavorable foreign currency effect.
Net sales for Asian operations increased $5.8 million, or 45 percent year-over-year. Higher average selling prices and a 17 percent increase in sales volume positively impacted the change in net sales by $2.7 million and $2.2 million, respectively. The sales volume growth was largely due to higher demand for products sold to our distribution partners and into the agricultural end market. The favorable impact of foreign currency translation positively impacted the change in net sales by $0.9 million
25
Surfactant operating income for the first quarter of 2021 increased $17.1 million, or 47 percent, versus operating income for the first quarter of 2020. Gross profit increased $20.0 million year-over-year and operating expenses were up $3.0 million. Comparisons of gross profit by region and total segment operating expenses and operating income follow:
|
|
For the Three Months Ended |
|
|
|
|
|
|
|
|
|
|||||
(Dollars in thousands) |
|
March 31, 2021 |
|
|
March 31, 2020 |
|
|
Increase |
|
|
Percent Change |
|
||||
Gross Profit and Operating Income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
North America |
|
$ |
54,056 |
|
|
$ |
41,163 |
|
|
$ |
12,893 |
|
|
|
31 |
|
Europe |
|
|
11,263 |
|
|
|
9,498 |
|
|
|
1,765 |
|
|
|
19 |
|
Latin America |
|
|
12,297 |
|
|
|
7,036 |
|
|
|
5,261 |
|
|
|
75 |
|
Asia |
|
|
2,267 |
|
|
|
2,157 |
|
|
|
110 |
|
|
|
5 |
|
Surfactants Segment Gross Profit |
|
$ |
79,883 |
|
|
$ |
59,854 |
|
|
$ |
20,029 |
|
|
|
33 |
|
Operating Expenses |
|
|
26,673 |
|
|
|
23,698 |
|
|
|
2,975 |
|
|
|
13 |
|
Surfactants Segment Operating Income |
|
$ |
53,210 |
|
|
$ |
36,156 |
|
|
$ |
17,054 |
|
|
|
47 |
|
Gross profit for North American operations increased $12.9 million, or 31 percent, between quarters primarily due to higher unit margins. The higher unit margins positively impacted the change in gross profit by $14.8 million and were mostly attributable to a more favorable product and customer mix and lower supply chain expenses due to the non-recurrence of the Millsdale, Illinois plant power outage in the first quarter of 2020. Sales volume declined five percent and negatively impacted the change in gross profit by $1.9 million. The decline in sales volume was mostly due to supply chain disruptions caused by the severe weather in Texas.
Gross profit for European operations increased $1.8 million, or 19 percent, due to the favorable impact of foreign currency translation, higher unit margins and slightly higher sales volumes. These items positively impacted the year-over-year change in gross profits by $0.9 million, $0.7 million and $0.1 million, respectively. A weaker U.S. dollar relative to the European euro and British pound sterling led to the favorable foreign currency translation effect.
Gross profit for Latin American operations increased $5.3 million, or 75 percent, between quarters primarily due to higher average unit margins and an eight percent increase in sales volume. These items positively impacted the change in gross profit by $6.0 million and $0.6 million, respectively. The higher unit margins primarily reflect a more favorable product and customer mix partially due to higher demand for products sold into the agricultural end market. The unfavorable impact of foreign currency translation negatively impacted the change in gross profit by $1.3 million.
Gross profit for Asia operations increased $0.1 million, or five percent, between quarters. Sales volume increased 17 percent year over year but was largely offset by lower average unit margins. The higher sales volume positively impacted the change in gross profit by $0.4 million whereas the lower average unit margins negatively impacted the change in gross profit by $0.3 million. Lower unit margins were mostly due to higher raw material cost.
Operating expenses for the Surfactants segment increased $3.0 million, or 13 percent, year-over-year. Most of the increase was due to higher salaries and fringe benefits.
Polymers
Polymer net sales for the first quarter of 2021 increased $43.9 million, or 41 percent, versus net sales for the same period of 2020. A 32 percent increase in sales volume favorably impacted the year-over-year change in net sales by $34.3 million. The increase in Polymer sales volume reflects a gradual recovery from COVID-19 related delays and cancellations of re-roofing and new construction projects, the 2021 acquisition of INVISTA’s aromatic polyester polyol business, and the non-recurrence of the plant power outage at the Company’s Millsdale, Illinois facility in the first quarter of 2020. Higher average selling prices and favorable impact of foreign currency translation positively impacted the change in net sales by $7.0 million and $2.6 million, respectively. A year-over-year comparison of net sales by region follows:
|
|
For the Three Months Ended |
|
|
|
|
|
|
|
|
|
|||||
(Dollars in thousands) |
|
March 31 |
|
|
March 31 |
|
|
Increase |
|
|
Percent |
|
||||
Net Sales |
|
2021 |
|
|
2020 |
|
|
|
|
|
|
change |
|
|||
North America |
|
$ |
70,878 |
|
|
$ |
61,841 |
|
|
$ |
9,037 |
|
|
|
15 |
|
Europe |
|
|
68,300 |
|
|
|
36,560 |
|
|
|
31,740 |
|
|
|
87 |
|
Asia and Other |
|
|
11,207 |
|
|
|
8,090 |
|
|
|
3,117 |
|
|
|
39 |
|
Total Polymers Segment |
|
$ |
150,385 |
|
|
$ |
106,491 |
|
|
$ |
43,894 |
|
|
|
41 |
|
Net sales for North American operations increased $9.0 million, or 15 percent, primarily due to a 28 percent increase in sales volume. The increase in sales volume positively impacted the change in net sales by $17.6 million. Sales volume of polyols used in rigid foam applications increased 25 percent during the quarter due to a gradual recovery from COVID-19 related delays of re-roofing
26
and new construction projects and the first quarter 2021 INVISTA acquisition. Sales volume of polyols used in rigid foam applications, excluding the impact of the INVISTA acquisition, increased eight percent. Sales volume of phthalic anhydride and specialty polyols increased 78 percent and 10 percent, respectively. The phthalic anhydride sales volume increase was largely due to the non-recurrence of the Millsdale plant power outage in 2020, which resulted in the Company declaring force majeure within this market. Lower average selling prices negatively impacted the change in net sales by $8.6 million.
Net sales for European operations increased $31.7 million, or 87 percent, year-over-year. Higher average selling prices and a 37 percent increase in sales volume favorably impacted the change in net sales by $16.1 million and $13.6 million, respectively. The higher average selling prices were primarily due to pass-through of higher raw material costs. The increase in sales volume reflects a gradual recovery from COVID-19 related delays of re-roofing and new construction projects and the first quarter 2021 INVISTA acquisition. Sales volume, excluding the impact of the INVISTA acquisition, increased seven percent. The favorable impact of foreign currency translation positively impacted the change in net sales by $2.0 million.
Net sales for Asia and Other operations increased $3.1 million, or 39 percent, due to a 33 percent increase in sales volume and the favorable impact of foreign currency translation. These items positively impacted the change in net sales by $2.7 million and $0.5 million, respectively. The sales volume growth was primarily attributable to higher demand within the livestock and cold storage markets within China. Lower average selling prices negatively impacted the change in net sales by $0.1 million.
Polymers operating income for the first quarter of 2021 increased $10.4 million, or 139%, versus operating income for the first quarter of 2020. Gross profit increased $11.0 million, or 76 percent, and operating expenses were up $0.6 million. Comparisons of gross profit by region and total segment operating expenses and operating income follow:
|
|
For the Three Months Ended |
|
|
|
|
|
|
|
|
|
|||||
(Dollars in thousands) |
|
March 31, 2021 |
|
|
March 31, 2020 |
|
|
Increase |
|
|
Percent Change |
|
||||
Gross Profit and Operating Income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
North America |
|
$ |
13,271 |
|
|
$ |
7,732 |
|
|
$ |
5,539 |
|
|
|
72 |
|
Europe |
|
|
10,996 |
|
|
|
5,652 |
|
|
|
5,344 |
|
|
|
95 |
|
Asia and Other |
|
|
1,263 |
|
|
|
1,131 |
|
|
|
132 |
|
|
|
12 |
|
Polymers Segment Gross Profit |
|
$ |
25,530 |
|
|
$ |
14,515 |
|
|
$ |
11,015 |
|
|
|
76 |
|
Operating Expenses |
|
|
7,579 |
|
|
|
6,999 |
|
|
|
580 |
|
|
|
8 |
|
Polymers Segment Operating Income |
|
$ |
17,951 |
|
|
$ |
7,516 |
|
|
$ |
10,435 |
|
|
|
139 |
|
Gross profit for North American operations increased $5.5 million, or 72 percent, due to higher unit margins and a 28 percent increase in sales volume. These two items favorably impacted the year-over-year change in gross profit by $3.3 million and $2.2 million, respectively. The higher unit margins are primarily due to the non-recurrence of the plant power outage at the Company’s Millsdale, Illinois facility in the first quarter of 2020 which resulted in higher maintenance, supply chain costs and unit overhead rates.
Gross profit for European operations increased $5.3 million, or 95 percent, versus the first quarter of 2020. The increase was primarily due to higher unit margins and 37 percent increase in sales volume. These two items favorably impacted the year-over-year change in gross profit by $2.8 million and $2.1 million respectively. A large part of the sales volume increase resulted from the 2021 INVISTA acquisition which also contributed to a more favorable product mix. The favorable impact of foreign currency translation positively impacted the change in gross profit by $0.4 million.
Gross profit for Asia and Other operations improved $0.1 million, or 12 percent, between quarters. Sales volume increased 33 percent year-over-year but was offset by lower average unit margins. The higher sales volume positively impacted the change in gross profit by $0.3 million and the lower unit margins negatively impacted the change in gross profit by $0.3 million. The lower unit margins reflect higher one-time tolling fees incurred during the first quarter of 2021. Foreign currency translation positively impacted the change in gross profit by $0.1 million.
Operating expenses for the Polymers segment increased $0.6 million, or eight percent, year-over-year.
Specialty Products
Specialty Products net sales were flat year-over-year. A four percent increase in sales volume was offset by lower average selling prices. Gross profit and operating income each decreased by $1.4 million. These decreases primarily reflect lower unit margins, attributable to raw material shortages and manufacturing challenges, within the Company’s medium chain triglycerides product line.
27
Corporate Expenses
Corporate expenses, which include deferred compensation, business restructuring and other operating expenses that are not allocated to the reportable segments, increased $12.2 million between quarters. Corporate expenses were $19.9 million in the first quarter of 2021 versus $7.7 million in 2020. This increase was primarily attributable to higher deferred compensation expense ($10.0 million), acquisition-related expenses ($1.0 million) and incentive-based compensation expenses.
The $10.0 million increase in deferred compensation expense was primarily due to a $7.79 per share increase in the market price of Company common stock in the first quarter of 2021 compared to a $13.98 per share decrease in the first quarter of 2020. The following table presents the quarter-end Company common stock market prices used in the computation of deferred compensation expenses for the three months ended March 31, 2021 and 2020:
|
|
2021 |
|
|
2020 |
|
|
2019 |
|
|||||||
|
|
March 31 |
|
|
December 31 |
|
|
March 31 |
|
|
December 31 |
|
||||
Company Common Stock Price |
|
$ |
127.11 |
|
|
$ |
119.32 |
|
|
$ |
88.46 |
|
|
$ |
102.44 |
|
LIQUIDITY AND CAPITAL RESOURCES
Overview
For the three months ended March 31, 2021, operating activities were a cash use of $11.7 million versus a use of $6.5 million for the comparable period in 2020. For the current year period, investing cash outflows totaled $223.8 million versus a cash outflow of $32.9 million in the prior year period. Financing activities were a source of $39.9 million versus a use of $14.4 million in the prior year period. Cash and cash equivalents decreased by $199.2 million compared to December 31, 2020, inclusive of a $3.7 million unfavorable foreign exchange rate impact.
At March 31, 2020, the Company’s cash and cash equivalents totaled $150.7 million. Cash in U.S. money market funds and demand deposit accounts totaled $33.4 million and $1.8 million, respectively. The Company’s non-U.S. subsidiaries held $115.5 million of cash outside the United States as of March 31, 2021.
Operating Activity
Net income in 2021 increased by $13.1 million versus the comparable period in 2020. Working capital was a cash use of $81.0 million in 2021 versus a use of $51.0 million in 2020.
Accounts receivable were a use of $63.2 million in 2021 compared to a use of $30.8 million for the comparable period of 2020. Inventories were a use of $7.5 million in 2021 versus a use of $0.4 million in 2020. Accounts payable and accrued liabilities were a use of $9.4 million in 2021 compared to a use of $16.6 million for the same period in 2020.
Working capital requirements were higher in 2021 compared to 2020 primarily due to the changes noted above. The higher accounts receivable cash usage in 2021 was largely due to higher sales volume related to the INVISTA acquisition. It is management’s opinion that the Company’s liquidity is sufficient to provide for potential increases in working capital requirements during 2021.
Investing Activity
Cash used for investing activities increased $190.8 million year-over-year. In the first quarter of 2021, the Company acquired INVISTA’s aromatic polyester polyol business and associated asset for $184.0 million, net of cash received. During the first quarter of 2021, the Company also acquired a fermentation plant located in Lake Providence, Louisiana for $3.5 million. Cash used for capital expenditures was $37.6 million in the first quarter of 2021 versus $33.2 million in the comparable prior year period.
For 2021, the Company estimates that total capital expenditures will range from $150 million to $170 million including growth initiatives, infrastructure and optimization spending in the United States, Germany and Mexico.
Financing Activity
Cash flow from financing activities was a source of $39.9 million in 2021 versus a use of $14.4 million in 2020. The increase in cash source is primarily due to borrowings from the Company’s revolving credit facility during the first quarter of 2021.
The Company purchases shares of its common stock in the open market or from its benefit plans from time to time to fund its own benefit plans and to mitigate the dilutive effect of new shares issued under its compensation plans. The Company may, from time to time, seek to retire or purchase additional amounts of its outstanding equity and/or debt securities through cash purchases and/or exchanges for other securities, in open market purchases, privately negotiated transactions or otherwise, including pursuant to plans meeting the requirements of Rule 10b5-1 promulgated by the SEC. Such repurchases or exchanges, if any, will depend on prevailing market conditions, the Company’s liquidity requirements, contractual restrictions and other factors. The amounts involved may be
28
material. In the three months ended March 31, 2021, the Company purchased 8,300 shares on the open market at a total cost of $1.0 million. At March 31, 2021, there were 167,574 shares remaining under the current share repurchase authorization.
Debt and Credit Facilities
Consolidated balance sheet debt increased by $49.7 million from $198.7 million to $248.4 million, primarily due to higher domestic debt which reflects borrowings from the Company’s revolving credit agreement during the first quarter of 2021. In 2021, net debt (which is defined as total debt minus cash – see the “Reconciliation of Non-GAAP Net Debt” section of this MD&A) increased by $248.9 million in the first quarter of 2021, from a negative $151.2 million to $97.7 million.
As of March 31, 2021, the ratio of total debt to total debt plus shareholders’ equity was 19.9 percent compared to 16.8 percent at December 31, 2020. As of March 31, 2021, the ratio of net debt to net debt plus shareholders’ equity was 8.9 percent, versus a negative 18.1 percent at December 31, 2020. See the “Reconciliation of Non-GAAP Net Debt” section in this MD&A. At March 31, 2021, the Company’s debt included $198.7 million of unsecured notes, with maturities ranging from 2021 through 2027, that were issued to insurance companies in private placement transactions pursuant to note purchase agreements (the Note Purchase Agreements), $45.0 million of short term loans borrowed under the revolving credit facility, and $4.7 million of foreign credit line borrowings. The proceeds from these note issuances have been the Company’s primary source of long-term debt financing and are supplemented by borrowings under bank credit facilities to meet short and medium-term liquidity needs.
On January 30, 2018, the Company entered a five-year committed $350 million multi-currency revolving credit facility with a syndicate of banks that matures on January 30, 2023. This credit agreement allows the Company to make unsecured borrowings, as requested from time to time, to finance working capital needs, permitted acquisitions, capital expenditures and for general corporate purposes. This unsecured facility is the Company’s primary source of short-term borrowings. As of March 31, 2021, the Company had outstanding loans totaling $45.0 million and letters of credit totaling $6.8 million under the revolving credit facility, with $298.2 million remaining available.
The Company anticipates that cash from operations, committed credit facilities and cash on hand will be sufficient to fund anticipated capital expenditures, working capital, dividends and other planned financial commitments for the foreseeable future.
Certain foreign subsidiaries of the Company maintain short-term bank lines of credit in their respective local currencies to meet working capital requirements as well as to fund capital expenditures and acquisitions. At March 31, 2021, the Company’s foreign subsidiaries had $4.7 million of outstanding debt.
The Company is subject to covenants under its material debt agreements that require the maintenance of minimum interest coverage and minimum net worth. These agreements also limit the incurrence of additional debt as well as the payment of dividends and repurchase of shares. Under the most restrictive of these debt covenants:
|
1. |
The Company is required to maintain a minimum interest coverage ratio, as defined within the agreements, of 3.50 to 1.00, for the preceding four calendar quarters. |
|
2. |
The Company is required to maintain a maximum net leverage ratio, as defined within the agreements, not to exceed 3.50 to 1.00. |
|
3. |
The Company is required to maintain net worth of at least $325.0 million. |
|
4. |
The Company is permitted to pay dividends and purchase treasury shares after December 31, 2017, in amounts of up to $100.0 million plus 100 percent of net income and cash proceeds of stock option exercises, measured cumulatively beginning December 31, 2017. The maximum amount of dividends that could have been paid within this limitation is disclosed as unrestricted retained earnings in Note 14, Debt, of the notes to the Company’s condensed consolidated financial statements (included in Item 1 of this Form 10-Q). |
The Company believes it was in compliance with all of its debt covenants as of March 31, 2021.
ENVIRONMENTAL AND LEGAL MATTERS
The Company’s operations are subject to extensive federal, state and local environmental laws and regulations and similar laws in the other countries in which the Company does business. Although the Company's environmental policies and practices are designed to ensure compliance with these laws and regulations, future developments and increasingly stringent environmental regulation may require the Company to make additional unforeseen environmental expenditures. The Company will continue to invest in the equipment and facilities necessary to comply with existing and future regulations. During the first three months of 2021 and 2020, the Company’s expenditures for capital projects related to the environment were $3.0 million and $0.7 million, respectively. These projects are capitalized and depreciated over their estimated useful lives, which are typically 10 years. Recurring costs associated with the operation and maintenance of facilities for waste treatment and disposal and managing environmental compliance in ongoing
29
operations at the Company’s manufacturing locations were $8.3 million and $10.0 million for the three months ended March 31, 2021 and 2020, respectively.
Over the years, the Company has received requests for information related to or has been named by the government as a potentially responsible party at a number of waste disposal sites where cleanup costs have been or may be incurred under CERCLA and similar state or foreign statutes. In addition, damages are being claimed against the Company in general liability actions for alleged personal injury or property damage in the case of some disposal and plant sites. The Company believes that it has made adequate provisions for the costs it is likely to incur with respect to the sites. It is the Company’s accounting policy to record liabilities when environmental assessments and/or remedial efforts are probable, and the cost or range of possible costs can be reasonably estimated. When no amount within the range is a better estimate than any other amount, the minimum is accrued. Estimating the possible costs of remediation requires making assumptions related to the nature and extent of contamination and the methods and resulting costs of remediation. Some of the factors on which the Company bases its estimates include information provided by decisions rendered by State and Federal environmental regulatory agencies, information provided by feasibility studies, and remedial action plans developed. After partial remediation payments at certain sites, the Company has estimated a range of possible environmental and legal losses of $22.9 million to $41.3 million at March 31, 2021 versus $22.9 million to $41.1 million at December 31, 2020. Within the range of possible environmental losses, management has currently concluded that no single amount is more likely to occur than any other amounts in the range and, thus, has accrued at the lower end of the range; these accruals totaled $22.9 million at March 31, 2021 and December 31, 2020. Because the liabilities accrued are estimates, actual amounts could differ materially from the amounts reported. Cash expenditures related to legal and environmental matters were $0.3 million for the three-month period ended March 31, 2021 compared to $0.9 million for the same period in 2020.
For certain sites, the Company has responded to information requests made by federal, state or local government agencies but has received no response confirming or denying the Company’s stated positions. As such, estimates of the total costs, or range of possible costs, of remediation, if any, or the Company’s share of such costs, if any, cannot be determined with respect to these sites. Consequently, the Company is unable to predict the effect thereof on the Company’s financial position, cash flows and results of operations. Based upon the Company’s present knowledge with respect to its involvement at these sites, the possibility of other viable entities’ responsibilities for cleanup, and the extended period over which any costs would be incurred, management believes that the Company has no liability at these sites and that these matters, individually and in the aggregate, will not have a material effect on the Company’s financial position. Certain of these matters are discussed in Item 1, Part 2, of the Company’s Annual Report on Form 10-K, Legal Proceedings, in this report and in other filings of the Company with SEC, which are available upon request from the Company. See also Note 8, Contingencies, to the Company’s condensed consolidated financial statements (included in Item 1 of this Form 10-Q) for a summary of the environmental proceedings related to certain environmental sites.
30
OUTLOOK
Management believes the Company’s Surfactant volumes in the North American consumer product end markets should recover following the supply chain disruptions caused by the severe weather in Texas during the first quarter of 2021. Additionally, management believes that heightened global consumer demand for disinfection, cleaning and personal wash products will continue and that demand for surfactants within the agricultural and oilfield markets will improve versus 2020. Global demand for rigid polyols continues to recover from pandemic-related delays and cancellations of re-roofing and new construction projects. This gradual recovery, combined with the Company’s first quarter 2021 acquisition of INVISTA's aromatic polyester polyol business, should position the Company’s Polymer segment to deliver growth versus prior year. Management believes the long-term prospects for the Polymer segment remain attractive as energy conservation efforts and more stringent building codes are expected to continue. Management believes its Specialty Products segment results will improve slightly year-over-year.
CRITICAL ACCOUNTING POLICIES
There have been no material changes to the critical accounting policies disclosed in the Company’s 2020 Annual Report on Form 10-K, except for the addition of the following:
Business Combinations
The Company makes acquisitions from time to time. When such acquisitions occur, the Company applies the accounting guidance per FASB ASC Topic 805, Business Combinations (ASC 805), to determine whether the acquisition should be treated as an asset acquisition or a business combination. When the acquisition meets the criteria of a business combination the Company recognizes the identifiable assets acquired and liabilities assumed at their estimated fair values as of the date of the acquisition. The Company recognizes goodwill for any portion of the purchase price that exceeds the sum of the net fair value of all the assets purchased in the acquisition and the liabilities assumed. Considerable estimates, complex judgments and assumptions are typically required to arrive at the fair value of elements acquired in a business combination, inclusive of discount rates, customer attrition rates, royalty rates, economic lives, and estimated future cash flows expected to be generated from the assets acquired. These items are typically most relevant to the fair valuation of identifiable intangible assets and property, plant and equipment.
In some instances, the purchase price allocation of an acquisition is not complete by the end of a reporting period. This situation most typically arises when an acquisition is complex and/or completed very close to the end of a reporting period and all necessary information is not available by the end of the reporting period in which the acquisition occurs. In these instances, the Company reports provisional amounts for any incomplete items and makes subsequent adjustments as necessary information becomes available or determines that additional information is not obtainable. Any subsequent adjustments could have a material impact on the Company’s financial condition or results of operations as they could impact the initial fair values assigned to intangible assets and property, plant and equipment and/or their estimated economic lives. ASC 805 requires purchase price allocations to be finalized within one year from the acquisition date.
Goodwill and Intangible Assets
The Company’s intangible assets include patents, agreements not to compete, trademarks, customer lists and relationships, technological and manufacturing know-how and goodwill, all of which were acquired as part of business combinations or asset acquisitions. Goodwill represents the excess of cost over the fair value of net assets acquired in a business combination. Intangible assets, other than goodwill, are determined to have either finite or indefinite useful lives. The Company currently has no indefinite-life intangible assets other than goodwill. Intangible assets with finite lives are amortized over the useful lives of the assets. Currently, the useful lives for the Company’s finite-life intangible assets are as follows: patents – 10 to15 years; non-compete agreements – three to five years; trademarks – five to 11 years; customer relationships – five to 20 years and know-how – five to 20 years. Finite-life intangible assets are tested for impairment when events or changes in circumstances indicate that the carrying value of an intangible asset may not be recoverable.
Goodwill is not amortized but is tested for impairment on a reporting unit level. The Company’s reporting units are typically defined as one level below operating segments and highly correlated to geographic regions. The Company tests goodwill for impairment annually (the Company conducts its goodwill impairment testing during the second quarter of each calendar year), or more frequently when events or changes in circumstances indicate it is more likely than not that the fair value of the reporting unit to which goodwill relates has declined below its carrying value. In this case, the Company would recognize an impairment charge for the amount by which the carrying value exceeds the reporting unit’s fair value. Goodwill is evaluated for impairment using qualitative and/or quantitative testing procedures. The Company has the option to first perform qualitative testing to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. If the Company chooses not to complete a qualitative assessment for a given reporting unit, or if the initial assessment indicates that it is more likely than not that the estimated fair value of a reporting unit is less than its carrying value, additional quantitative testing is performed.
31
When estimating a reporting unit’s fair value as part of the quantitative assessment, the Company uses a combination of market and income-based methodologies. The market approach uses a combination of earnings before interest, taxes, depreciation and amortization (EBITDA) and EBITDA multiples to estimate a reporting unit’s fair value. EBITDA multiples typically mirror similar businesses or comparative companies whose securities are actively traded in public markets. Significant degradation of either EBITDA or EBITDA multiples could result in a triggering event, requiring goodwill to be tested for impairment during an interim period. The income approach takes into consideration multiple variables, including forecasted sales volume and operating income, current industry and economic conditions, historical results and other elements to calculate the present value of future cash flows. The income approach fair value calculations include estimates of long-term growth rates and discount rates that are commensurate with the risks and uncertainty inherent in the respective reporting units. The Company reported no goodwill or intangible asset impairments in any of the periods presented in these condensed consolidated financial statements.
NON-GAAP RECONCILIATIONS
The Company believes that certain non-GAAP measures, when presented in conjunction with comparable GAAP measures, are useful for evaluating the Company’s performance and financial condition. Internally, the Company uses this non-GAAP information as an indicator of business performance and evaluates management’s effectiveness with specific reference to these indicators. These measures should be considered in addition to, not as substitutes for or superior to, measures of financial performance prepared in accordance with GAAP. The Company’s definitions of these measures may differ from similarly titled measures used by other entities.
Reconciliation of Non-GAAP Adjusted Net Income and Earnings Per Share
|
|
Three Months Ended March 31 |
|
|||||||||||||
(In millions, except per share amounts) |
|
2021 |
|
|
2020 |
|
||||||||||
|
|
Net Income |
|
|
Diluted EPS |
|
|
Net Income |
|
|
Diluted EPS |
|
||||
Net Income Attributable to the Company as Reported |
|
$ |
40.6 |
|
|
$ |
1.74 |
|
|
$ |
27.5 |
|
|
$ |
1.18 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deferred Compensation Expense (Income) (including related investment activity) |
|
|
2.0 |
|
|
|
0.09 |
|
|
|
(3.7 |
) |
|
|
(0.16 |
) |
Business Restructuring |
|
|
0.1 |
|
|
|
— |
|
|
|
0.4 |
|
|
|
0.02 |
|
Cash Settled Stock Appreciation Rights |
|
|
0.3 |
|
|
|
0.01 |
|
|
|
(1.1 |
) |
|
|
(0.04 |
) |
Cumulative Tax Effect on Above Adjustment Items |
|
|
(0.6 |
) |
|
|
(0.02 |
) |
|
|
1.1 |
|
|
|
0.04 |
|
Adjusted Net Income |
|
$ |
42.4 |
|
|
$ |
1.82 |
|
|
$ |
24.2 |
|
|
$ |
1.04 |
|
Management uses the non-GAAP adjusting net income metric to evaluate the Company’s operating performance. Management excludes the items listed in the table above because they are non-operational items. The cumulative tax effect was calculated using the statutory tax rates for the jurisdictions in which the noted transactions occurred.
Reconciliation of Non-GAAP Net Debt
Management uses the non-GAAP net debt metric to gain a more complete picture of the Company’s overall liquidity, financial flexibility and leverage level.
(In millions) |
|
March 31, 2021 |
|
|
December 31, 2020 |
|
||
Current Maturities of Long-Term Debt as Reported |
|
$ |
87.5 |
|
|
$ |
37.9 |
|
Long-Term Debt as Reported |
|
|
160.9 |
|
|
|
160.8 |
|
Total Debt as Reported |
|
|
248.4 |
|
|
|
198.7 |
|
Less Cash and Cash Equivalents as Reported |
|
|
(150.7 |
) |
|
|
(349.9 |
) |
Net Debt |
|
$ |
97.7 |
|
|
$ |
(151.2 |
) |
Equity |
|
$ |
1,002.3 |
|
|
$ |
986.7 |
|
Net Debt plus Equity |
|
$ |
1,100.0 |
|
|
$ |
835.5 |
|
Net Debt/(Net Debt plus Equity) |
|
|
9 |
% |
|
|
-18 |
% |
32
Item 3 – Quantitative and Qualitative Disclosures about Market Risk
There have been no material changes to the market risks described in the Company’s 2020 Annual Report on Form 10-K.
Item 4 – Controls and Procedures
|
a. |
Evaluation of Disclosure Controls and Procedures |
We have conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of March 31, 2021. Based on this evaluation of our disclosure controls and procedures, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of March 31, 2021, such that the information required to be disclosed in our Securities and Exchange Commission reports is recorded, processed, summarized and reported within the time periods specified by the rules and forms of the Exchange Act and is accumulated and communicated to management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosures.
|
b. |
Changes in Internal Control Over Financial Reporting |
There were no changes in the Company’s internal controls over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that occurred during the quarter ended March 31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Part II OTHER INFORMATION
Item 1 – Legal Proceedings
There have been no material changes to the legal proceedings disclosed in the Company’s 2020 Annual Report on Form 10-K.
Item 1A – Risk Factors
There have been no material changes to the risk factors disclosed in the Company’s 2020 Annual Report on Form 10-K.
Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds
Below is a summary by month of share purchase by the Company during the first quarter of 2021:
Month |
|
Total Number of Shares Purchased |
|
|
|
Average Price Paid per Share |
|
|
Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (1) |
|
|
Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs (1) |
|
||||
January 2021 |
|
|
381 |
|
(2) |
|
$ |
129.03 |
|
|
|
— |
|
|
|
175,874 |
|
February 2021 |
|
|
17,418 |
|
(3) |
|
$ |
119.18 |
|
|
|
8,300 |
|
(4) |
|
167,574 |
|
March 2021 |
|
|
12,317 |
|
(5) |
|
$ |
122.16 |
|
|
|
— |
|
|
|
167,574 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
30,116 |
|
|
|
$ |
120.52 |
|
|
|
8,300 |
|
|
|
167,574 |
|
|
(1) |
On February 19, 2013, the Company’s Board of Directors authorized the Company to repurchase up to 1,000,000 shares of its outstanding common stock. Under this program, which does not have an expiration date, repurchases may be made from time to time through open market or privately negotiated transactions, subject to applicable laws. |
|
|
(2) |
Represents shares of Company common stock tendered by employees to settle statutory withholding taxes related to the exercise of SARs. |
|
|
(3) |
Includes 8,944, 95 and 79 shares of Company common stock tendered by employees to settle statutory withholding taxes related to the distribution of deferred performance stock awards, the distribution of deferred management incentive compensation and the exercise of SARs, respectively. |
|
|
(4) |
Represents shares of Company common stock purchased on the open market. |
|
|
(5) |
Includes 10,747 and 1,570 shares of Company common stock tendered by employees to settle statutory withholding taxes related to the distribution of performance stock awards and the exercise of SARs, respectively. |
|
Item 3 – Defaults Upon Senior Securities
None
33
Item 4 – Mine Safety Disclosures
Not applicable
Item 5 – Other Information
None
Item 6 – Exhibits
Exhibit No. |
|
Description |
|
|
|
10.1* |
– |
|
|
|
|
31.1 |
– |
|
|
|
|
31.2 |
– |
|
|
|
|
32 |
– |
|
|
|
|
101.INS |
– |
Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the inline XBRL document |
|
|
|
101.SCH |
– |
Inline XBRL Taxonomy Extension Schema Document |
|
|
|
101.CAL |
– |
Inline XBRL Taxonomy Extension Calculation Linkbase Document |
|
|
|
101.DEF |
– |
Inline XBRL Taxonomy Extension Definition Document |
|
|
|
101.LAB |
– |
Inline XBRL Taxonomy Extension Label Linkbase Document |
|
|
|
101.PRE |
– |
Inline XBRL Taxonomy Extension Presentation Linkbase Document |
|
|
|
104 |
– |
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |
* |
Filed herewith |
34
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
STEPAN COMPANY |
Date: May 6, 2021
/s/ Luis E. Rojo |
Luis E. Rojo |
Vice President and Chief Financial Officer |
35